TWI760331B - 可溶性C5aR拮抗劑 - Google Patents
可溶性C5aR拮抗劑 Download PDFInfo
- Publication number
- TWI760331B TWI760331B TW106111387A TW106111387A TWI760331B TW I760331 B TWI760331 B TW I760331B TW 106111387 A TW106111387 A TW 106111387A TW 106111387 A TW106111387 A TW 106111387A TW I760331 B TWI760331 B TW I760331B
- Authority
- TW
- Taiwan
- Prior art keywords
- inhibitor
- group
- acid
- inhibitors
- alkylene
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims description 56
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 title description 2
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 150
- 150000003839 salts Chemical class 0.000 claims abstract description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 claims abstract description 21
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 claims abstract description 21
- 239000003112 inhibitor Substances 0.000 claims description 103
- -1 haloalkane radical Chemical class 0.000 claims description 98
- 239000003814 drug Substances 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- 229940124597 therapeutic agent Drugs 0.000 claims description 48
- 239000003446 ligand Substances 0.000 claims description 41
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 27
- 239000000556 agonist Substances 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 19
- 206010047115 Vasculitis Diseases 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 108060003951 Immunoglobulin Proteins 0.000 claims description 17
- 102000018358 immunoglobulin Human genes 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000003246 corticosteroid Substances 0.000 claims description 14
- 229960001334 corticosteroids Drugs 0.000 claims description 14
- 229960005205 prednisolone Drugs 0.000 claims description 14
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 14
- 150000003431 steroids Chemical class 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 229940044551 receptor antagonist Drugs 0.000 claims description 13
- 239000002464 receptor antagonist Substances 0.000 claims description 13
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 12
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 12
- 108010036949 Cyclosporine Proteins 0.000 claims description 12
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 12
- 239000002559 chemokine receptor antagonist Substances 0.000 claims description 12
- 229960001265 ciclosporin Drugs 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 229960004397 cyclophosphamide Drugs 0.000 claims description 12
- 229930182912 cyclosporin Natural products 0.000 claims description 12
- 239000003018 immunosuppressive agent Substances 0.000 claims description 12
- 229960004641 rituximab Drugs 0.000 claims description 12
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 11
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 11
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 10
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 10
- 229960000258 corticotropin Drugs 0.000 claims description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 10
- 201000008383 nephritis Diseases 0.000 claims description 10
- 229950010765 pivalate Drugs 0.000 claims description 10
- 229960004618 prednisone Drugs 0.000 claims description 10
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 10
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 9
- WKQCPUMQBMFPLC-ZWFCQKKLSA-N 11beta,21-Dihydroxypregn-4-ene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O WKQCPUMQBMFPLC-ZWFCQKKLSA-N 0.000 claims description 9
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 9
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 9
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 9
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 9
- 229960003957 dexamethasone Drugs 0.000 claims description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
- 229960002442 glucosamine Drugs 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 208000004235 neutropenia Diseases 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 108010029697 CD40 Ligand Proteins 0.000 claims description 8
- 102100032937 CD40 ligand Human genes 0.000 claims description 8
- 102100025406 Complement C1s subcomponent Human genes 0.000 claims description 8
- 108050005572 Complement C1s subcomponent Proteins 0.000 claims description 8
- 102400000739 Corticotropin Human genes 0.000 claims description 8
- 101800000414 Corticotropin Proteins 0.000 claims description 8
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 8
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 claims description 8
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- 229960002537 betamethasone Drugs 0.000 claims description 8
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 8
- 229960004577 laquinimod Drugs 0.000 claims description 8
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 229940092705 beclomethasone Drugs 0.000 claims description 7
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000003169 central nervous system Anatomy 0.000 claims description 7
- 229960002475 halometasone Drugs 0.000 claims description 7
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 208000003154 papilloma Diseases 0.000 claims description 7
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 6
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 6
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 6
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 6
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 6
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims description 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 6
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 6
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 6
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims description 6
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 208000009956 adenocarcinoma Diseases 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 229960005354 betamethasone sodium phosphate Drugs 0.000 claims description 6
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 claims description 6
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 6
- 229960004311 betamethasone valerate Drugs 0.000 claims description 6
- 229960004436 budesonide Drugs 0.000 claims description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- 229960003728 ciclesonide Drugs 0.000 claims description 6
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 6
- 229960004703 clobetasol propionate Drugs 0.000 claims description 6
- 229960003662 desonide Drugs 0.000 claims description 6
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims description 6
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims description 6
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 6
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 6
- 206010025135 lupus erythematosus Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 229960004584 methylprednisolone Drugs 0.000 claims description 6
- 229960001664 mometasone Drugs 0.000 claims description 6
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 claims description 6
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims description 6
- 229960005294 triamcinolone Drugs 0.000 claims description 6
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 6
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 6
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 6
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 6
- 229940070710 valerate Drugs 0.000 claims description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 5
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims description 5
- 201000003076 Angiosarcoma Diseases 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 5
- 102100028892 Cardiotrophin-1 Human genes 0.000 claims description 5
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 5
- 108010008165 Etanercept Proteins 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 5
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 5
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 5
- 206010021263 IgA nephropathy Diseases 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 5
- 206010027406 Mesothelioma Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 229960003697 abatacept Drugs 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 229960003099 amcinonide Drugs 0.000 claims description 5
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 claims description 5
- 230000001494 anti-thymocyte effect Effects 0.000 claims description 5
- 229960001102 betamethasone dipropionate Drugs 0.000 claims description 5
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 5
- 108010041776 cardiotrophin 1 Proteins 0.000 claims description 5
- 229960000403 etanercept Drugs 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 229960000890 hydrocortisone Drugs 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 206010024627 liposarcoma Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 206010027191 meningioma Diseases 0.000 claims description 5
- 230000005012 migration Effects 0.000 claims description 5
- 238000013508 migration Methods 0.000 claims description 5
- 229950003734 milatuzumab Drugs 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 229960005027 natalizumab Drugs 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 235000019260 propionic acid Nutrition 0.000 claims description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
- 230000003582 thrombocytopenic effect Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 4
- XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 claims description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 4
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 4
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims description 4
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 claims description 4
- WRFHGDPIDHPWIQ-UHFFFAOYSA-N 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O=C1N(CC=2C=C(COCC)C(=CC=2)C=2C(=CC=CC=2)S(=O)(=O)NC=2C(=C(C)ON=2)C)C(CCCC)=NC21CCCC2 WRFHGDPIDHPWIQ-UHFFFAOYSA-N 0.000 claims description 4
- MYIFLDFUXIHOCJ-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 MYIFLDFUXIHOCJ-UHFFFAOYSA-N 0.000 claims description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 4
- 208000016323 C3 glomerulonephritis Diseases 0.000 claims description 4
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims description 4
- 102100031168 CCN family member 2 Human genes 0.000 claims description 4
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims description 4
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims description 4
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 claims description 4
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 4
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 229940121968 Cyclin-dependent kinase 2 inhibitor Drugs 0.000 claims description 4
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 4
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 4
- 101710114790 Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 102100031334 Elongation factor 2 Human genes 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 4
- 229940087983 Erythropoietin receptor agonist Drugs 0.000 claims description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 4
- 108010071289 Factor XIII Proteins 0.000 claims description 4
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims description 4
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 101150022655 HGF gene Proteins 0.000 claims description 4
- 102000001554 Hemoglobins Human genes 0.000 claims description 4
- 108010054147 Hemoglobins Proteins 0.000 claims description 4
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 4
- 101150030450 IRS1 gene Proteins 0.000 claims description 4
- 102000009490 IgG Receptors Human genes 0.000 claims description 4
- 108010073807 IgG Receptors Proteins 0.000 claims description 4
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims description 4
- 102100022337 Integrin alpha-V Human genes 0.000 claims description 4
- 101710123022 Integrin alpha-V Proteins 0.000 claims description 4
- 102100033011 Integrin beta-6 Human genes 0.000 claims description 4
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims description 4
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims description 4
- 229940123187 Interferon receptor antagonist Drugs 0.000 claims description 4
- 102000006992 Interferon-alpha Human genes 0.000 claims description 4
- 108010047761 Interferon-alpha Proteins 0.000 claims description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 4
- 102000013691 Interleukin-17 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 4
- 102100030703 Interleukin-22 Human genes 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 208000011200 Kawasaki disease Diseases 0.000 claims description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 4
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 4
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 4
- 229940127171 LMB-2 Drugs 0.000 claims description 4
- 102100030635 Leukocyte elastase inhibitor Human genes 0.000 claims description 4
- 101710091916 Leukocyte elastase inhibitor Proteins 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 4
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims description 4
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 4
- 101100119865 Mus musculus Fcrla gene Proteins 0.000 claims description 4
- 102100033341 N-acetylmannosamine kinase Human genes 0.000 claims description 4
- 108010029147 N-acylmannosamine kinase Proteins 0.000 claims description 4
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 4
- 108010054395 P-selectin ligand protein Proteins 0.000 claims description 4
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 4
- 108091008611 Protein Kinase B Proteins 0.000 claims description 4
- 108090000315 Protein Kinase C Proteins 0.000 claims description 4
- 102000003923 Protein Kinase C Human genes 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 108010091769 Shiga Toxin 1 Proteins 0.000 claims description 4
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims description 4
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 claims description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 4
- 101710193588 T-cell antigen CD7 Proteins 0.000 claims description 4
- 101710179381 T-cell differentiation antigen CD6 Proteins 0.000 claims description 4
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 claims description 4
- 101150080074 TP53 gene Proteins 0.000 claims description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims description 4
- 239000004012 Tofacitinib Substances 0.000 claims description 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 4
- 102000004243 Tubulin Human genes 0.000 claims description 4
- 108090000704 Tubulin Proteins 0.000 claims description 4
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 4
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002487 adenosine deaminase inhibitor Substances 0.000 claims description 4
- 229960000548 alemtuzumab Drugs 0.000 claims description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 4
- 108010021281 angiotensin I (1-7) Proteins 0.000 claims description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 4
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 claims description 4
- 229960004669 basiliximab Drugs 0.000 claims description 4
- 229960005347 belatacept Drugs 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 4
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 229960001838 canakinumab Drugs 0.000 claims description 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 4
- 229950011318 cannabidiol Drugs 0.000 claims description 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 4
- 239000003536 cannabinoid receptor antagonist Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 229960002806 daclizumab Drugs 0.000 claims description 4
- PIBARDGJJAGJAJ-NQIIRXRSSA-N danicopan Chemical compound C(C)(=O)C1=NN(C2=CC=C(C=C12)C=1C=NC(=NC1)C)CC(=O)N1[C@@H](C[C@H](C1)F)C(=O)NC1=NC(=CC=C1)Br PIBARDGJJAGJAJ-NQIIRXRSSA-N 0.000 claims description 4
- 229960004120 defibrotide Drugs 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 4
- 229960005167 everolimus Drugs 0.000 claims description 4
- 229940012444 factor xiii Drugs 0.000 claims description 4
- 229960000556 fingolimod Drugs 0.000 claims description 4
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 230000002949 hemolytic effect Effects 0.000 claims description 4
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 4
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 4
- 229960001507 ibrutinib Drugs 0.000 claims description 4
- 229960002411 imatinib Drugs 0.000 claims description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 4
- 229940027941 immunoglobulin g Drugs 0.000 claims description 4
- 239000002596 immunotoxin Substances 0.000 claims description 4
- 229960000598 infliximab Drugs 0.000 claims description 4
- 108010021309 integrin beta6 Proteins 0.000 claims description 4
- 108010074109 interleukin-22 Proteins 0.000 claims description 4
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 4
- 229960002198 irbesartan Drugs 0.000 claims description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 4
- 229950003818 itolizumab Drugs 0.000 claims description 4
- 229960000681 leflunomide Drugs 0.000 claims description 4
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 4
- 239000003591 leukocyte elastase inhibitor Substances 0.000 claims description 4
- 208000012804 lymphangiosarcoma Diseases 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 4
- 229960002510 mandelic acid Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960005108 mepolizumab Drugs 0.000 claims description 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 4
- 229950000844 mizoribine Drugs 0.000 claims description 4
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 229940015638 narsoplimab Drugs 0.000 claims description 4
- 229960001346 nilotinib Drugs 0.000 claims description 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 4
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 4
- 108700025694 p53 Genes Proteins 0.000 claims description 4
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 4
- 229960005184 panobinostat Drugs 0.000 claims description 4
- 229960002340 pentostatin Drugs 0.000 claims description 4
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- 229960004919 procaine Drugs 0.000 claims description 4
- 239000003207 proteasome inhibitor Substances 0.000 claims description 4
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- PLQRBFAACWRSKF-LJTMIZJLSA-M sodium;n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]carbamodithioate Chemical compound [Na+].[S-]C(=S)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO PLQRBFAACWRSKF-LJTMIZJLSA-M 0.000 claims description 4
- 229950005814 sotrastaurin Drugs 0.000 claims description 4
- OAVGBZOFDPFGPJ-UHFFFAOYSA-N sotrastaurin Chemical compound C1CN(C)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 OAVGBZOFDPFGPJ-UHFFFAOYSA-N 0.000 claims description 4
- 229950002009 sparsentan Drugs 0.000 claims description 4
- 201000008753 synovium neoplasm Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 229960001967 tacrolimus Drugs 0.000 claims description 4
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- 229960003989 tocilizumab Drugs 0.000 claims description 4
- 229960001350 tofacitinib Drugs 0.000 claims description 4
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 229950003873 triciribine Drugs 0.000 claims description 4
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 claims description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 3
- 229940013085 2-diethylaminoethanol Drugs 0.000 claims description 3
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 claims description 3
- 208000003200 Adenoma Diseases 0.000 claims description 3
- 206010001233 Adenoma benign Diseases 0.000 claims description 3
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 3
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 3
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 claims description 3
- 208000029574 C3 glomerulopathy Diseases 0.000 claims description 3
- 229940123625 CD74 antagonist Drugs 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 102000011727 Caspases Human genes 0.000 claims description 3
- 108010076667 Caspases Proteins 0.000 claims description 3
- 201000005262 Chondroma Diseases 0.000 claims description 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 3
- FBRAWBYQGRLCEK-AVVSTMBFSA-N Clobetasone butyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CCC)[C@@]1(C)CC2=O FBRAWBYQGRLCEK-AVVSTMBFSA-N 0.000 claims description 3
- 108090000056 Complement factor B Proteins 0.000 claims description 3
- 102000003712 Complement factor B Human genes 0.000 claims description 3
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims description 3
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 3
- 201000005171 Cystadenoma Diseases 0.000 claims description 3
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- 206010024612 Lipoma Diseases 0.000 claims description 3
- 208000004852 Lung Injury Diseases 0.000 claims description 3
- 206010025219 Lymphangioma Diseases 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 3
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 claims description 3
- 208000001738 Nervous System Trauma Diseases 0.000 claims description 3
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 206010034277 Pemphigoid Diseases 0.000 claims description 3
- 241000721454 Pemphigus Species 0.000 claims description 3
- 229940120013 Protein kinase C alpha inhibitor Drugs 0.000 claims description 3
- 208000034541 Rare lymphatic malformation Diseases 0.000 claims description 3
- 206010038563 Reocclusion Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 208000005678 Rhabdomyoma Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 206010052568 Urticaria chronic Diseases 0.000 claims description 3
- 206010053648 Vascular occlusion Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims description 3
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 3
- 108700025316 aldesleukin Proteins 0.000 claims description 3
- 229960005310 aldesleukin Drugs 0.000 claims description 3
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 229950004993 asunercept Drugs 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 229960003270 belimumab Drugs 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001231 choline Drugs 0.000 claims description 3
- 208000024376 chronic urticaria Diseases 0.000 claims description 3
- 229960005465 clobetasone butyrate Drugs 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 208000002528 coronary thrombosis Diseases 0.000 claims description 3
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 3
- 208000002445 cystadenocarcinoma Diseases 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 3
- 239000003363 dihydroorotate dehydrogenase inhibitor Substances 0.000 claims description 3
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims description 3
- 206010013023 diphtheria Diseases 0.000 claims description 3
- 206010016629 fibroma Diseases 0.000 claims description 3
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 3
- 229960002383 halcinonide Drugs 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 3
- 201000010260 leiomyoma Diseases 0.000 claims description 3
- 229940121292 leronlimab Drugs 0.000 claims description 3
- 231100000515 lung injury Toxicity 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 3
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 3
- 230000002988 nephrogenic effect Effects 0.000 claims description 3
- 208000028412 nervous system injury Diseases 0.000 claims description 3
- 208000027134 non-immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 claims description 3
- 229960001199 olmesartan medoxomil Drugs 0.000 claims description 3
- 229960005010 orotic acid Drugs 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000008798 osteoma Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 208000004333 pleomorphic adenoma Diseases 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 229960004559 theobromine Drugs 0.000 claims description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 3
- 230000000472 traumatic effect Effects 0.000 claims description 3
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 229960000281 trometamol Drugs 0.000 claims description 3
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- LKVFMOMQYXIFRK-KSVAIKAXSA-N (3S,6S,9S,12S,18S,21S,27S,30S,33S,36S,42R,47R,50S,53S,56S)-42-amino-3-(4-aminobutyl)-36-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-9,18,30-tris(2-carboxyethyl)-27-[(1R)-1-hydroxyethyl]-50-[(4-hydroxyphenyl)methyl]-53-(1H-indol-3-ylmethyl)-6,12-dimethyl-2,5,8,11,14,17,20,26,29,32,35,38,41,49,52,55-hexadecaoxo-44,45-dithia-1,4,7,10,13,16,19,25,28,31,34,37,40,48,51,54-hexadecazatricyclo[54.3.0.021,25]nonapentacontane-47-carboxylic acid Chemical compound C[C@@H](O)[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]2CCCN2C1=O)C(O)=O LKVFMOMQYXIFRK-KSVAIKAXSA-N 0.000 claims description 2
- SCVHJVCATBPIHN-SJCJKPOMSA-N (3s)-3-[[(2s)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound N([C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)COC=1C(=C(F)C=C(F)C=1F)F)C(=O)C(=O)NC1=CC=CC=C1C(C)(C)C SCVHJVCATBPIHN-SJCJKPOMSA-N 0.000 claims description 2
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 claims description 2
- KKYABQBFGDZVNQ-UHFFFAOYSA-N 6-[5-[(cyclopropylamino)-oxomethyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-3-pyridinecarboxamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C1=CC=C(C(=O)NCC(C)(C)C)C=N1 KKYABQBFGDZVNQ-UHFFFAOYSA-N 0.000 claims description 2
- 108010009522 AMG623 peptibody Proteins 0.000 claims description 2
- 108010049501 AP301 peptide Proteins 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 claims description 2
- 239000005480 Olmesartan Substances 0.000 claims description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 2
- DDLPYOCJHQSVSZ-SSDOTTSWSA-N [4-[(2r)-1-(methanesulfonamido)-1-oxopropan-2-yl]phenyl] trifluoromethanesulfonate Chemical compound CS(=O)(=O)NC(=O)[C@H](C)C1=CC=C(OS(=O)(=O)C(F)(F)F)C=C1 DDLPYOCJHQSVSZ-SSDOTTSWSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 229950000920 aganirsen Drugs 0.000 claims description 2
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 claims description 2
- 229960002459 alefacept Drugs 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 229950010117 anifrolumab Drugs 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- 229950009925 atacicept Drugs 0.000 claims description 2
- 229960004965 begelomab Drugs 0.000 claims description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 claims description 2
- 229950003297 beperminogene perplasmid Drugs 0.000 claims description 2
- 229950004201 blisibimod Drugs 0.000 claims description 2
- 229960000455 brentuximab vedotin Drugs 0.000 claims description 2
- 229960001684 catridecacog Drugs 0.000 claims description 2
- 229950011033 cenicriviroc Drugs 0.000 claims description 2
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 claims description 2
- LPAUOXUZGSBGDU-STDDISTJSA-N chembl1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 claims description 2
- DREIJXJRTLTGJC-ZLBJMMTISA-N chembl3137308 Chemical compound C([C@H]1C[C@@](O)(C2)C3)C2C[C@H]3[C@H]1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-ZLBJMMTISA-N 0.000 claims description 2
- 229940088949 cinryze Drugs 0.000 claims description 2
- 229950001565 clazakizumab Drugs 0.000 claims description 2
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 claims description 2
- 108010017271 denileukin diftitox Proteins 0.000 claims description 2
- 229960002923 denileukin diftitox Drugs 0.000 claims description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 2
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 claims description 2
- 208000014616 embryonal neoplasm Diseases 0.000 claims description 2
- 229950000234 emricasan Drugs 0.000 claims description 2
- 229960000785 fluocinonide Drugs 0.000 claims description 2
- 229960003973 fluocortolone Drugs 0.000 claims description 2
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 claims description 2
- 229960002650 fluprednidene acetate Drugs 0.000 claims description 2
- DEFOZIFYUBUHHU-IYQKUMFPSA-N fluprednidene acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O DEFOZIFYUBUHHU-IYQKUMFPSA-N 0.000 claims description 2
- 229950004356 foralumab Drugs 0.000 claims description 2
- 229950005309 fostamatinib Drugs 0.000 claims description 2
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 claims description 2
- 229950003717 gevokizumab Drugs 0.000 claims description 2
- 229940097043 glucuronic acid Drugs 0.000 claims description 2
- 229960002706 gusperimus Drugs 0.000 claims description 2
- IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical compound NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 claims description 2
- 201000011066 hemangioma Diseases 0.000 claims description 2
- 102000044507 human SERPING1 Human genes 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 229950007937 inolimomab Drugs 0.000 claims description 2
- 229950001890 itacitinib Drugs 0.000 claims description 2
- 229960003648 ixazomib Drugs 0.000 claims description 2
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 2
- 229950010517 ladarixin Drugs 0.000 claims description 2
- 229950003265 losmapimod Drugs 0.000 claims description 2
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 claims description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 2
- 229950008814 momelotinib Drugs 0.000 claims description 2
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 229960003347 obinutuzumab Drugs 0.000 claims description 2
- 229950005751 ocrelizumab Drugs 0.000 claims description 2
- 229940013982 octagam Drugs 0.000 claims description 2
- 229960005117 olmesartan Drugs 0.000 claims description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 2
- 231100000590 oncogenic Toxicity 0.000 claims description 2
- 230000002246 oncogenic effect Effects 0.000 claims description 2
- 229950002610 otelixizumab Drugs 0.000 claims description 2
- 229960002404 palifermin Drugs 0.000 claims description 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 2
- 229950005157 peficitinib Drugs 0.000 claims description 2
- 229950009275 ponesimod Drugs 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002794 prednicarbate Drugs 0.000 claims description 2
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 claims description 2
- XEABSBMNTNXEJM-UHFFFAOYSA-N propagermanium Chemical compound OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O XEABSBMNTNXEJM-UHFFFAOYSA-N 0.000 claims description 2
- 229950002828 propagermanium Drugs 0.000 claims description 2
- 229940075993 receptor modulator Drugs 0.000 claims description 2
- KQDRVXQXKZXMHP-LLVKDONJSA-N reparixin Chemical compound CC(C)CC1=CC=C([C@@H](C)C(=O)NS(C)(=O)=O)C=C1 KQDRVXQXKZXMHP-LLVKDONJSA-N 0.000 claims description 2
- 229950005650 reparixin Drugs 0.000 claims description 2
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims description 2
- 229950000055 seliciclib Drugs 0.000 claims description 2
- 229950010077 sifalimumab Drugs 0.000 claims description 2
- 229950006094 sirukumab Drugs 0.000 claims description 2
- 229950008127 solnatide Drugs 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- CBPNZQVSJQDFBE-HGVVHKDOSA-N temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 claims description 2
- 229950010127 teplizumab Drugs 0.000 claims description 2
- 229940107955 thymoglobulin Drugs 0.000 claims description 2
- 229950010029 tiprelestat Drugs 0.000 claims description 2
- 229960003114 tixocortol pivalate Drugs 0.000 claims description 2
- BISFDZNIUZIKJD-XDANTLIUSA-N tixocortol pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O BISFDZNIUZIKJD-XDANTLIUSA-N 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 229940080778 Adenosine deaminase inhibitor Drugs 0.000 claims 2
- 229940124111 CD52 antagonist Drugs 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 2
- 150000004712 monophosphates Chemical class 0.000 claims 2
- CZRCFAOMWRAFIC-UHFFFAOYSA-N 5-(tetradecyloxy)-2-furoic acid Chemical compound CCCCCCCCCCCCCCOC1=CC=C(C(O)=O)O1 CZRCFAOMWRAFIC-UHFFFAOYSA-N 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 241001474374 Blennius Species 0.000 claims 1
- 229940082465 CD30 antagonist Drugs 0.000 claims 1
- 229940123169 Caspase inhibitor Drugs 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 claims 1
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 claims 1
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 1
- 101710097116 Glycosyltransferase 6 Proteins 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000005018 casein Substances 0.000 claims 1
- 235000021240 caseins Nutrition 0.000 claims 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims 1
- 229960005361 cefaclor Drugs 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 210000002149 gonad Anatomy 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- 229960000951 mycophenolic acid Drugs 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 208000037923 polyvascular disease Diseases 0.000 claims 1
- 229960000688 pomalidomide Drugs 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 25
- 238000002360 preparation method Methods 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 150000001412 amines Chemical class 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 35
- 235000019439 ethyl acetate Nutrition 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 26
- 239000011737 fluorine Substances 0.000 description 24
- 229910052731 fluorine Inorganic materials 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000012043 crude product Substances 0.000 description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 239000002253 acid Substances 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 235000008504 concentrate Nutrition 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 150000004702 methyl esters Chemical class 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 239000007937 lozenge Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 229910004809 Na2 SO4 Inorganic materials 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 230000000155 isotopic effect Effects 0.000 description 7
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 125000004404 heteroalkyl group Chemical group 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000007821 HATU Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 4
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 4
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 4
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 4
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 229960004365 benzoic acid Drugs 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 229940125721 immunosuppressive agent Drugs 0.000 description 4
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 4
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 229960003852 atezolizumab Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 229960001067 hydrocortisone acetate Drugs 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QUPFKBITVLIQNA-KPKJPENVSA-N (5e)-2-sulfanylidene-5-[[5-[3-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-1,3-thiazolidin-4-one Chemical compound FC(F)(F)C1=CC=CC(C=2OC(\C=C\3C(NC(=S)S/3)=O)=CC=2)=C1 QUPFKBITVLIQNA-KPKJPENVSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- ZIMLRKWQDLVPEK-UHFFFAOYSA-N 1-[4-(4-chloro-3-methoxyphenyl)piperazin-1-yl]-2-[3-(1H-imidazol-2-yl)pyrazolo[3,4-b]pyridin-1-yl]ethanone Chemical compound C1=C(Cl)C(OC)=CC(N2CCN(CC2)C(=O)CN2C3=NC=CC=C3C(C=3NC=CN=3)=N2)=C1 ZIMLRKWQDLVPEK-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- LUUMLYXKTPBTQR-UHFFFAOYSA-N 4-chloro-n-[5-methyl-2-(7h-pyrrolo[2,3-d]pyrimidine-4-carbonyl)pyridin-3-yl]-3-(trifluoromethyl)benzenesulfonamide Chemical compound C=1C(C)=CN=C(C(=O)C=2C=3C=CNC=3N=CN=2)C=1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 LUUMLYXKTPBTQR-UHFFFAOYSA-N 0.000 description 2
- JRWROCIMSDXGOZ-UHFFFAOYSA-N 4-tert-butyl-n-[4-chloro-2-(1-oxidopyridin-1-ium-4-carbonyl)phenyl]benzenesulfonamide Chemical compound C1=CC(C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=C(Cl)C=C1C(=O)C1=CC=[N+]([O-])C=C1 JRWROCIMSDXGOZ-UHFFFAOYSA-N 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000033116 Asbestos intoxication Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 2
- IVLCBPWOYZQKSF-DHIFEGFHSA-N CC1=C(CN(CCC[C@@H]2C(NC3=CC=C(C)C(C(F)(F)F)=C3)=O)[C@H]2C(C=C2)=CC=C2NC2CCCC2)C(F)=CC=C1 Chemical compound CC1=C(CN(CCC[C@@H]2C(NC3=CC=C(C)C(C(F)(F)F)=C3)=O)[C@H]2C(C=C2)=CC=C2NC2CCCC2)C(F)=CC=C1 IVLCBPWOYZQKSF-DHIFEGFHSA-N 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 108010065524 CD52 Antigen Proteins 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 2
- HFOBENSCBRZVSP-LKXGYXEUSA-N C[C@@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc(no1)[C@@H](N)CO)C(O)=O Chemical compound C[C@@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc(no1)[C@@H](N)CO)C(O)=O HFOBENSCBRZVSP-LKXGYXEUSA-N 0.000 description 2
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010048832 Colon adenoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 2
- 101000798902 Homo sapiens Atypical chemokine receptor 4 Proteins 0.000 description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 2
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 2
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 101150069255 KLRC1 gene Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 2
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 229940122696 MAP kinase inhibitor Drugs 0.000 description 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- 208000005890 Neuroma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 2
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
- 206010046392 Ureteric cancer Diseases 0.000 description 2
- 206010046431 Urethral cancer Diseases 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 206010003441 asbestosis Diseases 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 208000026900 bile duct neoplasm Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000011111 cardboard Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- CGLRXKACBSXHIU-UHFFFAOYSA-N chloromethyl carbamate Chemical compound NC(=O)OCCl CGLRXKACBSXHIU-UHFFFAOYSA-N 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004474 heteroalkylene group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 2
- 229940044173 iodine-125 Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 208000025402 neoplasm of esophagus Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 201000003913 parathyroid carcinoma Diseases 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940121497 sintilimab Drugs 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 208000037959 spinal tumor Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 208000022271 tubular adenoma Diseases 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RJOJSMIZZYHNQG-JTQLQIEISA-N (2s)-2,5-bis[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)(C)OC(=O)NCCC[C@@H](C(O)=O)NC(=O)OC(C)(C)C RJOJSMIZZYHNQG-JTQLQIEISA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- CANZBRDGRHNSGZ-NSHDSACASA-N (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-NSHDSACASA-N 0.000 description 1
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
- IBABAURSJXMCQJ-QWRGUYRKSA-N (2s)-3-methyl-2-[[(2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]amino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)OC(C)(C)C IBABAURSJXMCQJ-QWRGUYRKSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IBQYJXBNELPBNT-WXXKFALUSA-L (e)-but-2-enedioate;tetrabutylazanium Chemical compound [O-]C(=O)\C=C\C([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC IBQYJXBNELPBNT-WXXKFALUSA-L 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- FKASAVXZZLJTNX-UHFFFAOYSA-N 2-(dimethylamino)acetic acid;hydrochloride Chemical compound [Cl-].C[NH+](C)CC(O)=O FKASAVXZZLJTNX-UHFFFAOYSA-N 0.000 description 1
- BWPKSNMGVTYXQQ-VIFPVBQESA-N 2-[[(2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O BWPKSNMGVTYXQQ-VIFPVBQESA-N 0.000 description 1
- HWBAHOVOSOAFLE-UHFFFAOYSA-N 2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(=O)NCC(O)=O HWBAHOVOSOAFLE-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ACQYZSFXPXXIHL-UHFFFAOYSA-N 2-phenylmethoxycarbonyl-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1CC2=CC=CC=C2C(C(=O)O)N1C(=O)OCC1=CC=CC=C1 ACQYZSFXPXXIHL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- SMSCFZLMSBEZQU-UHFFFAOYSA-N 3-[(4-methylpiperazin-4-ium-1-yl)methyl]benzoate Chemical compound C1CN(C)CCN1CC1=CC=CC(C(O)=O)=C1 SMSCFZLMSBEZQU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical group C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010089414 Anaphylatoxins Proteins 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241001649081 Dina Species 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229910003944 H3 PO4 Inorganic materials 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- BXRMEWOQUXOLDH-LURJTMIESA-N L-Histidine methyl ester Chemical compound COC(=O)[C@@H](N)CC1=CN=CN1 BXRMEWOQUXOLDH-LURJTMIESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000015537 Protein Kinase C-alpha Human genes 0.000 description 1
- 108010050276 Protein Kinase C-alpha Proteins 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- VOLMSPGWNYJHQQ-UHFFFAOYSA-N Pyranone Natural products CC1=C(O)C(=O)C(O)CO1 VOLMSPGWNYJHQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 1
- HCBRAEWDLZUPNL-UHFFFAOYSA-N [I+].CCCC[N+](CCCC)(CCCC)CCCC Chemical compound [I+].CCCC[N+](CCCC)(CCCC)CCCC HCBRAEWDLZUPNL-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960004229 alclometasone dipropionate Drugs 0.000 description 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- MZDBWZZCIXRCBI-UHFFFAOYSA-N bis(phenylmethoxy)phosphoryloxymethyl carbonochloridate Chemical compound C=1C=CC=CC=1COP(=O)(OCOC(=O)Cl)OCC1=CC=CC=C1 MZDBWZZCIXRCBI-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229940126681 complement 5a receptor antagonist Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- UCQFCFPECQILOL-UHFFFAOYSA-N diethyl hydrogen phosphate Chemical compound CCOP(O)(=O)OCC UCQFCFPECQILOL-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229940125397 factor b inhibitor Drugs 0.000 description 1
- NSBWHQUKWQCNFU-UHFFFAOYSA-N formylazanium;chloride;hydrochloride Chemical compound Cl.Cl.NC=O NSBWHQUKWQCNFU-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical group CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000001037 lung lymphoma Diseases 0.000 description 1
- 201000003866 lung sarcoma Diseases 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- SCZVXVGZMZRGRU-UHFFFAOYSA-N n'-ethylethane-1,2-diamine Chemical compound CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 229940061584 phosphoramidic acid Drugs 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 231100000336 radiotoxic Toxicity 0.000 description 1
- 230000001690 radiotoxic effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- TWEGKFXBDXYJIU-UHFFFAOYSA-M sodium;2-methylpropanoate Chemical compound [Na+].CC(C)C([O-])=O TWEGKFXBDXYJIU-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 230000003156 vasculitic effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
Description
已在文獻(例如,Sumichika, H.等人,J. Biol. Chem.
(2002), 277, 49403-49407)中描述基於非肽之C5a受體拮抗劑,且已報告其有效地治療大鼠中之內毒素休克(Stracham, A.J.等人,J. of Immunol.
(2000), 164(12): 6560-6565);且有效地治療大鼠模型中之IBD (Woodruff, T.M.等人,J of Immunol.
, 2003, 171: 5514-5520)。亦已在以下公司及機構之專利文獻中描述基於非肽之C5a受體調節劑:Neurogen Corporation (例如,WO 2004/043925、WO 2004/018460、WO 2005/007087、WO 03/082826、WO 03/08828、WO 02/49993、WO 03/084524);Dompe S.P.A. (WO 02/029187);昆士蘭大學(The University of Queenland) (WO 2004/100975);及ChemoCentryx, Inc. (WO 2010/075257及WO 2011/163640)。 文獻中存在相當多的實驗性證據表明C5a之增加的含量伴有多種疾病及病症,尤其自體免疫及發炎性疾病及病症。此項技術中需要C5a受體(C5aR)之新的小型有機分子調節劑(例如,促效劑、偏促效劑且較佳地拮抗劑),其適用於抑制與增加的過敏毒素活性水準相關聯之致病事件(例如,趨化性)。 儘管可獲得如WO 2010/075257及WO 2011/163640中所描述之C5aR拮抗劑化合物,但仍需要具有經改良溶解性特徵之相關化合物,該等化合物可以適用於靜脈內遞送之方式調配且亦提供類似於WO 2010/075257及WO 2011/163640中之化合物的治療效益。
在一個態樣中,本文提供具有式(I)之化合物或其醫藥學上可接受之鹽,其中: R1
選自由以下各者組成之群:H、-O-CH2
-O-P(O)ORa
ORb
、-O-C(O)-C1-6
伸烷基-L2
-X1
、O-P(O)ORa
ORb
及-O-C(O)-A1
-(C1-3
伸烷基)n
-C4-7
雜環基,其中C4-7
雜環基視情況經1至6個Rc
基團取代; A1
選自由以下各者組成之群:C6-10
芳基、C3-10
環烷基、C5-10
雜芳基及C5-10
雜環基,該等基團中之每一者視情況經可相同或不同的1至5個Rx
取代; n為0或1; L2
選自由以下各者組成之群:鍵、-O-C(O)-C1-6
伸烷基-及-NRd
-C(O)-C1-6
伸烷基-; X1
獨立地選自由以下各者組成之群:-NRe
Rf
、-P(O)ORa
ORb
、-O-P(O)ORa
ORb
及-CO2
H; R2
選自由以下各者組成之群:H、-L3
-C1-6
伸烷基-L4
-X2
、-L3
-(C1-6
伸烷基)m
-A2
-X2
、-P(O)ORa
OC(O)-C1-6
烷基、-P(O)ORa
NRg
Rh
及-P(O)ORa
ORb
; L3
獨立地選自由-C(O)-O-及-C(O)-組成之群; L4
獨立地選自由以下各者組成之群:鍵、-O-C(O)-C2-6
伸烯基-、-O-C(O)-C1-6
伸烷基-及-NRd
-C(O)-C1-6
伸烷基-,其中-NRd
-C(O)-C1-6
伸烷基-及-O-C(O)-C1-6
伸烷基-中之C1-6
伸烷基視情況經NRe
Rf
取代; X2
獨立地選自由以下各者組成之群:-NRk
Rl
、-P(O)ORa
ORb
、-O-P(O)ORa
ORb
及-CO2
H; m為0或1; A2
選自由以下各者組成之群:C6-10
芳基、C3-10
環烷基、C5-10
雜芳基及C5-10
雜環基,該等基團中之每一者視情況經可相同或不同的1至5個Rx
取代; R3
為H或-L5
-P(O)ORa
ORb
,其中L5
獨立地選自由鍵及-CH2
-O-組成之群; 各Rx
獨立地選自由以下各者組成之群:鹵素、C1-6
烷基、C1-6
鹵烷基、C1-6
雜烷基、CN、NRy
Rz
、SRy
及ORy
; 各Rc
獨立地選自由以下各者組成之群:鹵素、C1-6
烷基、C1-6
鹵烷基、C1-6
雜烷基、CN、NRy
Rz
、SRy
及ORy
; 各Ra
、Rb
、Rd
、Re
、Rf
、Rg
、Rk
、Rl
、Ry
及Rz
獨立地選自由H及C1-6
烷基組成之群; 各Rh
獨立地選自由H及C1-6
烷基組成之群,其中C1-6
烷基視情況經1至5個取代基取代,該等取代基獨立地選自CO2
H、NRi
Rj
、C6-10
芳基、C3-10
環烷基、C5-10
雜芳基及C5-10
雜環基,其中各Ri
及Rj
獨立地為H或C1-6
烷基;且 其中R1
、R2
及R3
中之兩者為H,且R1
、R2
及R3
中之另一者不為H。 除本文所提供之化合物以外,本發明進一步提供含有一或多種此等化合物之醫藥組合物以及在治療方法中使用此等化合物之方法,其主要用以治療與C5a信號傳遞活性相關聯之疾病。
相關申請案之交叉參考
本申請案係根據35 U.S.C. § 119(e)主張2016年4月4日申請之美國臨時申請案第62/317,721號之權益的申請案,該申請案以其全文引用之方式併入本文中。聯邦資助研究與開發下的發明權利聲明
不適用對緊密光碟上提交之「序列表」、表格或電腦程式列表附錄之引用
不適用I. 縮寫及定義
如本文所用之術語「一(a/an)」或「該」不僅包括一個成員之態樣,且亦包括超過一個成員之態樣。舉例而言,除非上下文另外明確規定,否則單數形式「一(a/an)」及「該」包括複數個指示物。因此,舉例而言,對「一細胞(a cell)」之提及包括複數個此類細胞,且對「該藥劑(the agent)」之提及包括對熟習此項技術者已知之一或多種藥劑之提及,等等。 術語「約」及「大約」一般應意謂考慮量測之性質或精確度,所量測量之可接受的誤差度。典型的例示性誤差度在給定值或值範圍的百分之20 (%)內、較佳在10%內且更佳在5%內。替代地,且尤其在生物系統中,術語「約」及「大約」可意謂在給定值之數量級內,較佳在5倍內且更佳在2倍內的值。除非另外說明,否則本文中給定之數值量為近似值,意謂當未明確陳述時可推斷術語「約」或「大約」。 除非另外說明,否則術語「烷基」本身或作為另一取代基之部分意謂具有指定碳原子數目(亦即,C1-8
意謂一至八個碳)之直鏈或分支鏈烴基。烷基之實例包括甲基、乙基、正丙基、異丙基、正丁基、第三丁基、異丁基、第二丁基、正戊基、正己基、正庚基、正辛基及其類似者。術語「烷基」就其最廣義而言亦意謂包括諸如烯基及炔基之彼等不飽和基團。術語「烯基」係指具有一或多個雙鍵之不飽和烷基。類似地,術語「炔基」係指具有一或多個參鍵之不飽和烷基。此等不飽和烷基之實例包括乙烯基、2-丙烯基、巴豆基、2-異戊烯基、2-(丁二烯基)、2,4-戊二烯基、3-(1,4-戊二烯基)、乙炔基、1-丙炔基及3-丙炔基、3-丁炔基及高級同源物及異構體。術語「環烷基」係指具有指定數目個環原子(例如,C3-6
環烷基)且完全飽和或在環頂點之間具有不超過一個雙鍵之烴環。「環烷基」亦意謂係指雙環及多環烴環,諸如雙環[2.2.1]庚烷、雙環[2.2.2]辛烷等。術語「雜環烷基」或「雜環基」係指含有一至五個選自N、O及S之雜原子作為環頂點的環烷基,其中氮及硫原子視情況經氧化,且氮原子視情況經四級銨化。雜環烷基可為單環、雙環或多環系統。環雜烷基之非限制性實例包括吡咯啶、咪唑啶、吡唑啶、丁內醯胺、戊內醯胺、咪唑啶酮、乙內醯脲、二氧雜環戊烷、鄰苯二甲醯亞胺、哌啶、1,4-二噁烷、嗎啉、硫代嗎啉、硫代嗎啉-S-氧化物、硫代嗎啉-S,S-氧化物、哌嗪、哌喃、吡啶酮、3-吡咯啉、硫代哌喃、吡喃酮、四氫呋喃、四氫噻吩、啶及其類似物。雜環烷基可經由環碳或雜原子連接至分子之其餘部分。 術語「伸烷基」本身或作為另一取代基之部分意謂衍生自烷烴之二價基團,如由-CH2
CH2
CH2
CH2
-所例示。典型地,烷基(或伸烷基)將具有1至24個碳原子,在本發明中具有10個或更少碳原子之彼等基團為較佳的。「低碳烷基」或「低碳伸烷基」為一般具有四個或更少碳原子之較短鏈烷基或伸烷基。類似地,「伸烯基」及「伸炔基」分別係指具有雙鍵或參鍵之「伸烷基」之不飽和形式。 除非另外說明,否則術語「雜烷基」本身或與另一術語組合意謂穩定的直鏈或分支鏈或環烴基或其組合,其由所陳述數目個碳原子及一至三個選自由O、N、Si及S組成之群的雜原子組成,且其中氮及硫原子可視情況經氧化且氮雜原子可視情況經四級銨化。雜原子O、N及S可位於雜烷基之任何內部位置處。雜原子Si可位於雜烷基之任何位置處,包括烷基與分子之其餘部分連接之位置。實例包括-CH2
-CH2
-O-CH3
、-CH2
-CH2
-NH-CH3
、-CH2
-CH2
-N(CH3
)-CH3
、-CH2
-S-CH2
-CH3
、-CH2
-CH2
-S(O)-CH3
、-CH2
-CH2
-S(O)2
-CH3
、-CH=CH-O-CH3
、-Si(CH3
)3
、-CH2
-CH=N-OCH3
及-CH=CH-N(CH3
)-CH3
。至多兩個雜原子可為連續的,諸如-CH2
-NH-OCH3
及-CH2
-O-Si(CH3
)3
。類似地,除非另外說明,否則術語「雜烯基」及「雜炔基」本身或與另一術語組合分別意謂含有所陳述數目個碳且具有一至三個選自由O、N、Si及S組成之群的雜原子之烯基或炔基,且其中氮及硫原子可視情況經氧化且氮雜原子可視情況經四級銨化。雜原子O、N及S可位於雜烷基之任何內部位置處。 術語「伸雜烷基」本身或作為另一取代基之部分意謂衍生自雜烷基之飽和或不飽和或多元不飽和二價基團,如由-CH2
-CH2
-S-CH2
CH2
-及-CH2
-S-CH2
-CH2
-NH-CH2
-、-O-CH2
-CH=CH-、-CH2
-CH=C(H)CH2
-O-CH2
-及-S-CH2
-C≡C-所例示。對於伸雜烷基而言,雜原子亦可佔據任一或兩個鏈末端(例如伸烷氧基、伸烷二氧基、伸烷基胺基、伸烷基二胺基及其類似物)。 術語「烷氧基」、「烷基胺基」及「烷硫基」(或硫代烷氧基)以其習知含義使用,且指分別經由氧原子、胺基或硫原子連接至分子之其餘部分之彼等烷基。另外,對於二烷基胺基,烷基部分可為相同或不同且亦可經組合以形成具有各連接之氮原子之3至7員環。因此,表示為-NRa
Rb
之基團意謂包括哌啶基、吡咯啶基、嗎啉基、氮雜環丁基及其類似基團。 除非另外說明,否則術語「鹵基」或「鹵素」本身或作為另一取代基之部分意謂氟、氯、溴或碘原子。另外,諸如「鹵烷基」之術語意謂包括單鹵烷基及多鹵烷基。舉例而言,術語「C1-4
鹵烷基」意謂包括三氟甲基、2,2,2-三氟乙基、4-氯丁基、3-溴丙基及其類似基團。 除非另外說明,否則術語「芳基」意謂多元不飽和、通常為芳族之烴基,其可為單環或稠合在一起或共價連接之多個環(高達三個環)。術語「雜芳基」係指含有一至五個選自N、O及S之雜原子之芳基(或環),其中氮及硫原子視情況經氧化,且氮原子視情況經四級銨化。雜芳基可經由雜原子連接至分子之其餘部分。芳基之非限制性實例包括苯基、萘基及聯二苯,而雜芳基之非限制性實例包括吡啶基、噠嗪基、吡嗪基、嘧啶基、三嗪基、喹啉基、喹喏啉基、喹唑啉基、㖕啉基、酞嗪基、苯并三嗪基、嘌呤基、苯并咪唑基、苯并吡唑基、苯并三唑基、苯并異噁唑基、異苯并呋喃基、異吲哚基、吲哚嗪基、苯并三嗪基、噻吩并吡啶基、噻吩并嘧啶基、吡唑并嘧啶基、咪唑并吡啶、苯并噻唑基、苯并呋喃基、苯并噻吩基、吲哚基、喹啉基、異喹啉基、異噻唑基、吡唑基、吲唑基、喋啶基、咪唑基、三唑基、四唑基、噁唑基、異噁唑基、噻二唑基、吡咯基、噻唑基、呋喃基、噻吩基及其類似物。上文所提及之芳基及雜芳基環系統中之每一者的取代基選自下文所描述之可接受的取代基之群。 為簡潔起見,術語「芳基」在與其他術語組合使用時(例如芳氧基、芳基硫醇基、芳基烷基)包括如上文所定義之芳基及雜芳基環兩者。由此,術語「芳基烷基」意謂包括芳基連接至烷基之彼等基團(例如,苯甲基、苯乙基、吡啶基甲基及其類似基團)。 在一些實施例中,上文之術語(例如,「烷基」、「芳基」及「雜芳基」)將包括指定基團之經取代及未經取代形式兩者。下文提供各類基團之較佳取代基。為簡潔起見,術語芳基及雜芳基將指如下文所提供之經取代或未經取代型式,而術語「烷基」及相關脂族基團意謂係指未經取代型式,除非指示為經取代的。 烷基(包括通常被稱為伸烷基、烯基、炔基及環烷基之彼等基團)之取代基可為選自以下各者之各種基團:-鹵素、-OR'、-NR'R''、-SR'、-SiR'R''R'''、-OC(O)R'、-C(O)R'、-CO2
R'、-CONR'R''、-OC(O)NR'R''、-NR''C(O)R'、-NR'-C(O)NR''R'''、-NR''C(O)2
R'、-NH-C(NH2
)=NH、-NR'C(NH2
)=NH、-NH-C(NH2
)=NR'、-S(O)R'、-S(O)2
R'、-S(O)2
NR'R''、-NR'S(O)2
R''、-CN及-NO2
,其數目介於零至(2 m'+1)之範圍內,其中m'為此類基團中碳原子之總數。R'、R''及R'''各自獨立地指氫、未經取代之C1-8
烷基、未經取代之雜烷基、未經取代之芳基、經1至3個鹵素取代之芳基、未經取代之C1-8
烷基、C1-8
烷氧基或C1-8
硫代烷氧基或未經取代之芳基-C1-4
烷基。當R'及R''連接至同一氮原子時,其可與氮原子組合形成3員、4員、5員、6員或7員環。舉例而言,-NR'R''意謂包括1-吡咯啶基及4-嗎啉基。如本身或作為另一基團之部分使用之術語「醯基」係指其中最靠近基團連接點之碳上的兩個取代基經取代基=O置換的烷基(例如-C(O)CH3
、-C(O)CH2
CH2
OR'及其類似基團)。 類似地,芳基及雜芳基之取代基係變化的且一般選自:-鹵素、-OR'、-OC(O)R'、-NR'R''、-SR'、-R'、-CN、-NO2
、-CO2
R'、-CONR'R''、-C(O)R'、-OC(O)NR'R''、-NR''C(O)R'、-NR''C(O)2
R'、-NR'-C(O)NR''R'''、-NH-C(NH2
)=NH、-NR'C(NH2
)=NH、-NH-C(NH2
)=NR'、-S(O)R'、-S(O)2
R'、-S(O)2
NR'R''、-NR'S(O)2
R''、-N3
、全氟(C1
-C4
)烷氧基及全氟(C1
-C4
)烷基,其數目介於零至芳族環系統上開放價數之總數的範圍內;且其中R'、R''及R'''獨立地選自氫、C1-8
烷基、C3-6
環烷基、C2-8
烯基、C2-8
炔基、未經取代之芳基及雜芳基、(未經取代之芳基)-C1-4
烷基及未經取代之芳氧基-C1-4
烷基。其他適合取代基包括藉由1至4個碳原子之伸烷基繫鏈連接至環原子之以上芳基取代基中之每一者。 芳基或雜芳基環之相鄰原子上之取代基中之兩者可視情況經式-T-C(O)-(CH2
)q
-U-之取代基置換,其中T及U獨立地為-NH-、-O-、-CH2
-或單鍵,且q為0至2之整數。替代地,芳基或雜芳基環之相鄰原子上之取代基中之兩者可視情況經式-A-(CH2
)r
-B-之取代基置換,其中A及B獨立地為-CH2
-、-O-、-NH-、-S-、-S(O)-、-S(O)2
-、-S(O)2
NR'-或單鍵,且r為1至3之整數。由此形成之新環之單鍵中之一者可視情況經雙鍵置換。替代地,芳基或雜芳基環之相鄰原子上之取代基中之兩者可視情況經式-(CH2
)s
-X-(CH2
)t
-之取代基置換,其中s及t獨立地為0至3之整數,且X為-O-、-NR'-、-S-、-S(O)-、-S(O)2
-或-S(O)2
NR'-。-NR'-及-S(O)2
NR'-中之取代基R'選自氫或未經取代之C1-6
烷基。 如本文所用,術語「雜原子」意謂包括氧(O)、氮(N)、硫(S)及矽(Si)。 術語「醫藥學上可接受之鹽」意謂包括視在本文所描述之化合物上所存在之特定取代基而定,用相對無毒之酸或鹼製備之活性化合物的鹽。當本發明之化合物含有相對酸性官能基時,可藉由使該等化合物之中性形式與足夠量的所需鹼在無溶劑下或在適合惰性溶劑中接觸來獲得鹼加成鹽。衍生自醫藥學上可接受之無機鹼的鹽之實例包括鋁鹽、銨鹽、鈣鹽、銅鹽、鐵鹽、亞鐵鹽、鋰鹽、鎂鹽、錳鹽、亞錳鹽、鉀鹽、鈉鹽、鋅鹽及其類似鹽。衍生自醫藥學上可接受之有機鹼的鹽包括一級、二級及三級胺之鹽,包括經取代之胺、環狀胺、天然存在之胺及其類似物,諸如精胺酸、甜菜鹼、咖啡因、膽鹼、N,N'-二苯甲基乙二胺、二乙胺、2-二乙胺基乙醇、2-二甲胺基乙醇、乙醇胺、乙二胺、N-乙基嗎啉、N-乙基哌啶、還原葡糖胺、葡糖胺、組胺酸、海卓胺、異丙胺、離胺酸、甲基還原葡糖胺、嗎啉、哌嗪、哌啶、多元胺樹脂、普魯卡因(procaine)、嘌呤、可可豆鹼、三乙胺、三甲胺、三丙胺、緩血酸胺及其類似物。當本發明之化合物含有相對鹼性官能基時,可藉由使該等化合物之中性形式與足夠量的所需酸在無溶劑下或在適合惰性溶劑中接觸來獲得酸加成鹽。醫藥學上可接受之酸加成鹽之實例包括:衍生自無機酸之酸加成鹽,該等無機酸如鹽酸、氫溴酸、硝酸、碳酸、一氫碳酸、磷酸、一氫磷酸、二氫磷酸、硫酸、一氫硫酸、氫碘酸或亞磷酸及其類似物;以及衍生自相對無毒性有機酸之鹽,該等有機酸如乙酸、丙酸、異丁酸、丙二酸、苯甲酸、丁二酸、辛二酸、反丁烯二酸、杏仁酸、鄰苯二甲酸、苯磺酸、對甲苯磺酸、檸檬酸、酒石酸、甲磺酸及其類似物。亦包括諸如精胺酸及其類似物之胺基酸的鹽,及如葡糖醛酸或半乳糖醛酸及其類似物之有機酸的鹽(參見例如Berge, S.M.等人, 「Pharmaceutical Salts」,Journal of Pharmaceutical Science
,1977
,66
, 1-19)。本發明之某些特定化合物含有允許該等化合物轉化成鹼加成鹽或酸加成鹽之鹼性及酸性官能基兩者。本發明之某些特定化合物含有超過一種酸性官能基或超過一種鹼性官能基。在彼等情況下,術語「或其醫藥學上可接受之鹽」意謂包涵多鹽化合物,例如二Na鹽、二HCl鹽。 化合物之中性形式可藉由使鹽與鹼或酸接觸且以習知方式分離母體化合物而再生。化合物之母體形式與各種鹽形式的不同之處在於某些物理特性,諸如在極性溶劑中之溶解度,但出於本發明之目的,在其他方面,該等鹽等同於化合物之母體形式。 本發明之某些化合物可以非溶劑化形式以及溶劑化形式(包括水合形式)存在。一般而言,該等溶劑化形式等效於非溶劑化形式,且意欲包涵於本發明之範疇內。本發明之某些化合物可以多種結晶形式或非晶形式存在。一般而言,所有物理形式皆等同地用於本發明涵蓋之用途且意欲在本發明之範疇內。 本發明之某些化合物具有不對稱碳原子(光學中心)或雙鍵;外消旋體、非對映異構體、幾何異構體、區位異構體及個別異構體(例如,單獨的對映異構體)皆意欲涵蓋於本發明之範疇內。當出現立體化學描述(例如,虛線或楔形的鍵)時,其意謂指示存在異構體中之一者且實質上不含另一異構體之化合物。『實質上不含』另一異構體指示兩種異構體之至少80/20比率,更佳90/10或95/5或更高。在一些實施例中,異構體中之一者將以至少99%之量存在。 本發明之化合物亦可在構成此類化合物之原子中之一或多者處含有非天然比例之原子同位素。舉例而言,化合物可經諸如氚(3
H)、碘-125 (125
I)或碳-14 (14
C)之放射性同位素進行放射性標記。本發明化合物之所有同位素變體無論是否具放射性均意欲涵蓋於本發明之範疇內。舉例而言,可製備化合物以使得任何數目之氫原子經氘(2
H)同位素置換。本發明之化合物亦可在構成此類化合物之原子中之一或多者處含有非天然比例之原子同位素。非天然比例之同位素可定義為介於在自然界中發現之量至由100%所討論之原子組成之量的範圍內。舉例而言,化合物可併有放射性同位素,諸如氚(3
H)、碘-125 (125
I)或碳-14 (14
C);或非放射性同位素,諸如氘(2
H)或碳-13 (13
C)。此等同位素變體可為在本申請案內他處描述之彼等者提供額外效用。舉例而言,本發明化合物之同位素變體可具有額外效用,包括(但不限於)作為診斷及/或顯影試劑或作為細胞毒性/輻射毒性治療劑。另外,本發明化合物之同位素變體可具有改變之藥物動力學及藥效學特徵,其可有助於治療期間增強之安全性、耐受性或功效。本發明化合物之所有同位素變體無論是否具放射性均意欲涵蓋於本發明之範疇內。II. 化合物
在一個態樣中,本發明提供具有下式(I)之化合物或其醫藥學上可接受之鹽,其中: R1
選自由以下各者組成之群:H、-O-CH2
-O-P(O)ORa
ORb
、-O-C(O)-C1-6
伸烷基-L2
-X1
、O-P(O)ORa
ORb
及-O-C(O)-A1
-(C1-3
伸烷基)n
-C4-7
雜環基,其中C4-7
雜環基視情況經1至6個Rc
基團取代; A1
選自由以下各者組成之群:C6-10
芳基、C3-10
環烷基、C5-10
雜芳基及C5-10
雜環基,該等基團中之每一者視情況經可相同或不同的1至5個Rx
取代; n為0或1; L2
選自由以下各者組成之群:鍵、-O-C(O)-C1-6
伸烷基-及-NRd
-C(O)-C1-6
伸烷基-; X1
獨立地選自由以下各者組成之群:-NRe
Rf
、-P(O)ORa
ORb
、-O-P(O)ORa
ORb
及-CO2
H; R2
選自由以下各者組成之群:H、-L3
-C1-6
伸烷基-L4
-X2
、-L3
-(C1-6
伸烷基)m
-A2
-X2
、-P(O)ORa
OC(O)-C1-6
烷基、-P(O)ORa
NRg
Rh
及-P(O)ORa
ORb
; L3
獨立地選自由-C(O)-O-及-C(O)-組成之群; L4
獨立地選自由以下各者組成之群:鍵、-O-C(O)-C2-6
伸烯基-、-O-C(O)-C1-6
伸烷基-及-NRd
-C(O)-C1-6
伸烷基-,其中-NRd
-C(O)-C1-6
伸烷基-及-O-C(O)-C1-6
伸烷基-中之C1-6
伸烷基可視情況經NRe
Rf
取代; X2
獨立地選自由以下各者組成之群:-NRk
Rl
、-P(O)ORa
ORb
、-O-P(O)ORa
ORb
及-CO2
H; m為0或1; A2
選自由以下各者組成之群:C6-10
芳基、C3-10
環烷基、C5-10
雜芳基及C5-10
雜環基,該等基團中之每一者視情況經可相同或不同的1至5個Rx
取代; R3
為H或-L5
-P(O)ORa
ORb
,其中L5
獨立地選自由鍵及-CH2
-O-組成之群; 各Rx
獨立地選自由以下各者組成之群:鹵素、C1-6
烷基、C1-6
鹵烷基、C1-6
雜烷基、CN、NRy
Rz
、SRy
及ORy
; 各Rc
獨立地選自由以下各者組成之群:鹵素、C1-6
烷基、C1-6
鹵烷基、C1-6
雜烷基、CN、NRy
Rz
、SRy
及ORy
; 各Ra
、Rb
、Rd
、Re
、Rf
、Rg
、Rk
、Rl
、Ry
及Rz
獨立地選自由H及C1-6
烷基組成之群; 各Rh
獨立地選自由H及C1-6
烷基組成之群,其中C1-6
烷基視情況經1至5個取代基取代,該等取代基獨立地選自CO2
H、NRi
Rj
、C6-10
芳基、C3-10
環烷基、C5-10
雜芳基及C5-10
雜環基,其中各Ri
及Rj
獨立地為H或C1-6
烷基;且 其中R1
、R2
及R3
中之兩者為H,且R1
、R2
及R3
中之另一者不為H。 在一組實施例中,提供式(I)化合物或其醫藥學上可接受之鹽,其中R1
選自由以下各者組成之群:O-(CO)-C1-6
伸烷基-NRe
Rf
、O-(CO)-C1-6
伸烷基-NRd
(CO)-C1-6
伸烷基-NRe
Rf
、O-P(O)ORa
ORb
、O-CH2
-O-P(O)ORa
ORb
及O-(CO)-C6-10
伸芳基-C1-3
伸烷基-C4-7
雜環基,其中C4-7
雜環基選自由哌啶基、哌嗪基、吡咯啶基、嗎啉基及氮雜環丁基組成之群,且其中哌啶基、哌嗪基、吡咯啶基、嗎啉基及氮雜環丁基視情況經1至6個Rc
基團取代。 在另一組實施例中,提供式(I)化合物或其醫藥學上可接受之鹽,其中R1
選自由以下各者組成之群: 及。 在又一組實施例中,提供式(I)化合物或其醫藥學上可接受之鹽,其中R1
選自由以下各者組成之群:及。 在再一組實施例中,提供式(I)化合物或其醫藥學上可接受之鹽,其中R1
為。 在另一組實施例中,提供式(I)化合物或其醫藥學上可接受之鹽,其中R1
為。 在另其他實施例中,提供式(I)化合物或其醫藥學上可接受之鹽,其中R3
選自由-CH2
-O-P(O)ORa
ORb
及-P(O)ORa
ORb
組成之群。 在又一組實施例中,提供式(I)化合物或其醫藥學上可接受之鹽,其中R3
選自由以下各者組成之群:及。 在再一組實施例中,提供式(I)化合物或其醫藥學上可接受之鹽,其中R3
為。 在另一組實施例中,提供式(I)化合物或其醫藥學上可接受之鹽,其中R3
為。 在其他實施例中,提供式(I)化合物或其醫藥學上可接受之鹽,其中R2
選自由以下各者組成之群:-(CO)-C1-6
伸烷基-NRk
Rl
、-(CO)-O-C1-6
伸烷基-O-P(O)ORa
ORb
、-P(O)ORa
O(CO)-C1-6
烷基、-P(O)ORa
NRg
Rh
、-(CO)-O-C1-6
伸烷基-O-(CO)-C2-6
伸烯基-CO2
H、-(CO)-C1-6
伸烷基-NRd
(CO)-C1-6
伸烷基-NRk
Rl
,其中C1-6
伸烷基-NRk
Rl
可視情況經NRe
Rf
、-(CO)-O-C1-6
伸烷基-O-(CO)-C1-6
伸烷基-NRk
Rl
及-(CO)-O-C1-6
伸烷基-C6-10
芳基-O-P(O)ORa
ORb
取代,其中C6-10
芳基視情況經可相同或不同的1至5個Rx
取代。 在某些所選實施例中,R2
選自由以下各者組成之群:。 在所選實施例中,提供選自由以下各者組成之群的化合物: 或其醫藥學上可接受之鹽。 除了上文所提供之化合物以外,亦提供彼等化合物之醫藥學上可接受之鹽。在一些實施例中,該等醫藥學上可接受之鹽選自:銨、鈣、鎂、鉀、鈉、鋅、精胺酸、甜菜鹼、咖啡鹼、膽鹼、N,N'-二苯甲基乙二胺、二乙胺、2-二乙胺基乙醇、2-二甲胺基乙醇、乙醇胺、乙二胺、N-乙基嗎啉、N-乙基哌啶、還原葡糖胺、葡糖胺、組胺酸、海卓胺、異丙胺、離胺酸、甲基還原葡糖胺、嗎啉、哌嗪、哌啶、普魯卡因、嘌呤、可可豆鹼、三乙胺、三甲胺、三丙胺、緩血酸胺、鹽酸、碳酸、一氫碳酸、磷酸、一氫磷酸、二氫磷酸、乙酸、丙酸、異丁酸、丙二酸、苯甲酸、丁二酸、辛二酸、反丁烯二酸、杏仁酸、鄰苯二甲酸、苯磺酸、對甲苯磺酸、檸檬酸、酒石酸、甲磺酸、精胺酸、葡糖醛酸及半乳糖醛酸。在一些實施例中,醫藥學上可接受之鹽選自:銨、鈣、鎂、鉀、鈉、鹽酸、碳酸、一氫碳酸、磷酸、一氫磷酸、二氫磷酸、乙酸、丙酸、異丁酸、丙二酸、苯甲酸、丁二酸、辛二酸、反丁烯二酸、杏仁酸、鄰苯二甲酸、苯磺酸、對甲苯磺酸、檸檬酸、酒石酸、甲磺酸、精胺酸、葡糖醛酸及半乳糖醛酸。在一些實施例中,醫藥學上可接受之鹽為鈉或鹽酸。III. 藥物組合物
除上文所提供之化合物以外,用於調節人類及動物中之C5aR活性的組合物將通常含有醫藥載劑或稀釋劑。 如本文中所使用之術語「組合物」意欲涵蓋包含規定量之規定成份的產品,以及直接或間接由規定量之規定成份之組合產生的任何產品。「醫藥學上可接受」意謂載劑、稀釋劑或賦形劑必須與調配物之其他成份相容且對其接受者無害。 用於本發明化合物之投與的醫藥組合物可宜以單位劑型呈現且可藉由藥劑學及藥物遞送技術中熟知之方法中之任一者製備。所有方法均包括使活性成份與構成一或多種附屬成份之載劑結合的步驟。一般而言,藉由使活性成份與液體載劑或細粉狀固體載劑或兩者均勻且緊密地結合,且接著在必要時使產品成形為所需調配物,來製備醫藥組合物。在醫藥組合物中,活性目標化合物之包括量足以對疾病之過程或病況起所需作用。 含有活性成份之醫藥組合物可呈適用於口服使用之形式,例如呈錠劑、糖衣錠、口含錠、水性或油性懸浮液、分散性粉劑或粒劑、乳液及自乳化劑(如美國專利申請案2002-0012680中所描述)、硬性或軟性膠囊、糖漿、酏劑、溶液、口腔貼片、口服凝膠、口嚼錠、咀嚼錠劑、起泡粉劑及起泡錠劑形式。意欲用於口服使用之組合物可根據用於製造醫藥組合物之技術中已知之任何方法製備,且此類組合物可含有一或多種選自由以下組成之群的試劑:甜味劑、調味劑、著色劑、抗氧化劑及防腐劑以便提供醫藥學上精緻且適口的製劑。錠劑含有與醫藥學上可接受之無毒賦形劑摻合的活性成份,該等賦形劑適用於製造錠劑。此等賦形劑可為例如:惰性稀釋劑,諸如纖維素、二氧化矽、氧化鋁、碳酸鈣、碳酸鈉、葡萄糖、甘露糖醇、山梨糖醇、乳糖、磷酸鈣或磷酸鈉;粒化劑及崩解劑,例如玉米澱粉或褐藻酸;結合劑,例如PVP、纖維素、PEG、澱粉、明膠或阿拉伯膠;及潤滑劑,例如硬脂酸鎂、硬脂酸或滑石。錠劑可不包覆包衣或其可藉由已知技術包覆包衣(腸溶或以其他方式)以延遲在胃腸道中之崩解及吸收,且從而經較長時間段提供持續作用。舉例而言,可採用時間延遲材料,諸如單硬脂酸甘油酯或二硬脂酸甘油酯。其亦可藉由美國專利第4,256,108號、第4,166,452號及第4,265,874號中所描述之技術來包覆包衣,以形成用以控制釋放之滲透性治療錠劑。 用於口服使用之調配物亦可呈硬性明膠膠囊之形式,其中活性成份與惰性固體稀釋劑(例如碳酸鈣、磷酸鈣或高嶺土、各種平均尺寸之聚乙二醇(PEG) (例如,PEG400、PEG4000))及某些界面活性劑(諸如十六醇聚氧乙烯醚或solutol)混合;或呈軟性明膠膠囊之形式,其中活性成份與水或油介質(例如花生油、液體石蠟或橄欖油)混合。另外,乳液可用非水可混溶成份(諸如油)製備且用界面活性劑(諸如單或二酸甘油酯、PEG酯及其類似物)穩定化。 水性懸浮液含有與適合於製造水性懸浮液之賦形劑混雜的活性材料。此類賦形劑為懸浮劑,例如羧甲基纖維素鈉、甲基纖維素、羥基丙基甲基纖維素、海藻酸鈉、聚乙烯吡咯啶酮、黃蓍膠以及阿拉伯膠;分散劑或濕潤劑可為天然存在之磷脂,例如卵磷脂,或環氧烷與脂肪酸的縮合產物,例如聚氧乙烯硬脂酸酯,或氧化乙烯與長鏈脂族醇的縮合產物,例如十七伸乙基氧基十六醇,或氧化乙烯與衍生自脂肪酸及己糖醇的偏酯的縮合產物,諸如聚氧乙烯山梨糖醇單油酸酯,或氧化乙烯與衍生自脂肪酸及己糖醇酐的偏酯的縮合產物,例如聚乙烯脫水山梨糖醇單油酸酯。水性懸浮液亦可含有一或多種防腐劑,例如對羥基苯甲酸乙酯或對羥基苯甲酸正丙酯;一或多種著色劑;一或種調味劑;以及一或種甜味劑,諸如蔗糖或糖精。 油性懸浮液可藉由使活性成份懸浮於植物油(例如花生油、橄欖油、芝麻油或椰子油)中或礦物油(諸如液體石蠟)中來調配。油性懸浮液可含有增稠劑,例如蜂蠟、硬石蠟或鯨蠟醇。可添加甜味劑(諸如上述彼等甜味劑)及調味劑,以提供適口之經口製劑。此等組合物可藉由添加抗氧化劑(諸如抗壞血酸)來保存。 適用於藉由添加水製備水性懸浮液之分散性粉劑及粒劑提供活性成份與分散劑或濕潤劑、懸浮劑及一或多種防腐劑之摻合物。適合的分散劑或濕潤劑及懸浮劑由上文已提及之彼等物例示。亦可存在其他賦形劑,例如甜味劑、調味劑以及著色劑。 本發明醫藥組合物亦可呈水包油乳液形式。油相可為植物油,例如橄欖油或花生油;或礦物油,例如液體石蠟,或此等之混合物。適合之乳化劑可為天然存在之膠狀物,例如阿拉伯膠或黃蓍膠;天然存在之磷脂,例如大豆、卵磷脂;及衍生自脂肪酸及己醣醇酐之酯或偏酯,例如脫水山梨糖醇單油酸酯;及該等偏酯與氧化乙烯之縮合產物,例如聚氧乙烯脫水山梨糖醇單油酸酯。乳液亦可含有甜味劑及調味劑。 糖漿及酏劑可用例如丙三醇、丙二醇、山梨糖醇、葡萄糖或蔗糖之甜味劑來調配。此類調配物亦可含有緩和劑、防腐劑及調味劑以及著色劑。口服溶液可與例如環糊精、PEG及界面活性劑組合製備。 醫藥組合物可呈無菌可注射水性或油性懸浮液形式。此懸浮液可根據已知技術使用上文已提及之適合的分散劑或濕潤劑及懸浮劑調配。無菌可注射製劑亦可為於無毒非經腸可接受之稀釋劑或溶劑中之無菌可注射溶液或懸浮液,例如呈於1,3-丁二醇中之溶液形式。在可接受之媒劑及溶劑中,可採用的為水、林格氏溶液(Ringer's solution)及等張氯化鈉溶液。此外,無菌不揮發性油習知地用作溶劑或懸浮介質。出於此目的,可使用任何溫和非揮發性油,包括合成的單甘油酯或二甘油酯。另外,諸如油酸之脂肪酸可用於製備可注射劑。 本發明化合物亦可以用於經直腸投與藥物之栓劑形式投與。可藉由將藥物與適合無刺激性賦形劑混合來製備此等組合物,該賦形劑在常溫下為固體但在直腸溫度下為液體且因此將在直腸中熔融以釋放藥物。此類材料包括可可脂及聚乙二醇。另外,可藉助於溶液或軟膏經由眼部遞送來投與化合物。再者,標的化合物之經皮遞送可藉助於離子導入貼片及其類似物實現。對於體表使用,採用含有本發明化合物之乳膏、軟膏、凝膠劑、溶液或懸浮液等。如本文所使用,體表應用亦意謂包括使用漱口水及漱口劑。 本發明之化合物亦可與載劑偶合,該載劑為作為靶向藥物載劑之合適聚合物。此類聚合物可包括聚乙烯吡咯啶酮、哌喃共聚物、聚羥基-丙基-甲基丙烯醯胺-酚、聚羥乙基-天冬醯胺-酚或經軟脂醯基殘基取代之聚氧化乙烯-聚離胺酸。此外,本發明化合物可與載劑偶合,該載劑為適用於達成藥物之控制釋放的一類生物可降解聚合物,例如聚乳酸、聚乙醇酸、聚乳酸與聚乙醇酸之共聚物、聚ε己內酯、聚羥基丁酸、聚原酸酯、聚縮醛、聚二氫哌喃、聚氰基丙烯酸酯及水凝膠之交聯或兩性嵌段共聚物。聚合物及半透性聚合物基質可形成為成形製品,諸如瓣膜、血管內支架、導管、輔具及其類似物。在本發明之一個實施例中,本發明化合物與形成為血管內支架或血管內支架移植物裝置的聚合物或半透性聚合物基質偶合。 提供一種包含本發明化合物或其醫藥學上可接受之鹽及醫藥學上可接受之賦形劑的醫藥組合物。 在一些實施例中,該醫藥組合物經調配用於靜脈內投與。 在一些實施例中,該醫藥組合物包含一或多種其他治療劑。 在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:皮質類固醇、類固醇、免疫抑制劑、免疫球蛋白G促效劑、二肽基肽酶IV抑制劑、淋巴細胞功能抗原-3受體拮抗劑、介白素-2配位體、介白素-1 β配位體抑制劑、IL-2受體α次單位抑制劑、HGF基因刺激劑、IL-6拮抗劑、IL-5拮抗劑、α 1抗胰蛋白酶刺激劑、類大麻鹼受體拮抗劑、組蛋白脫乙醯基酶抑制劑、AKT蛋白激酶抑制劑、CD20抑制劑、Abl酪胺酸激酶抑制劑、JAK酪胺酸激酶抑制劑、TNF α配位體抑制劑、血紅蛋白調節劑、TNF拮抗劑、蛋白酶體抑制劑、CD3調節劑、Hsp 70家族抑制劑、免疫球蛋白促效劑、CD30拮抗劑、微管蛋白拮抗劑、神經鞘胺醇-1-磷酸酯受體-1促效劑、結締組織生長因子配位體抑制劑、卡斯蛋白酶抑制劑、促腎上腺皮質激素配位體、Btk酪胺酸激酶抑制劑、補體C1s子組分抑制劑、紅血球生成素受體促效劑、B-淋巴細胞刺激子配位體抑制劑、週期蛋白依賴型激酶-2抑制劑、P-選擇素醣蛋白配位體-1刺激劑、mTOR抑制劑、延長因子2抑制劑、細胞黏附分子抑制劑、XIII因子促效劑、鈣調神經磷酸酶抑制劑、免疫球蛋白G1促效劑、肌核苷單磷酸去氫酶抑制劑、補體C1s子組分抑制劑、胸苷激酶調節劑、細胞毒性T-淋巴細胞蛋白-4調節劑、血管緊張素II受體拮抗劑、血管緊張素II受體調節劑、TNF超家族受體12A拮抗劑、CD52拮抗劑、腺苷脫胺酶抑制劑、T細胞分化抗原CD6抑制劑、FGF-7配位體、二氫乳清酸去氫酶抑制劑、CCR5趨化介素拮抗劑、CCR2趨化介素拮抗劑、Syk酪胺酸激酶抑制劑、I型干擾素受體拮抗劑、α干擾素配位體抑制劑、巨噬細胞遷移抑制因子抑制劑、整合素α-V/β-6拮抗劑、半胱胺酸蛋白酶刺激劑、p38 MAP激酶抑制劑、TP53基因抑制劑、志賀樣毒素I (Shiga like toxin I)抑制劑、海藻糖基轉移酶6刺激劑、介白素22配位體、CXCR1趨化介素拮抗劑、CXCR4趨化介素拮抗劑、IRS1基因抑制劑、蛋白激酶C刺激劑、蛋白激酶C α抑制劑、CD74拮抗劑、免疫球蛋白γ Fc受體IIB拮抗劑、T細胞抗原CD7抑制劑、CD95拮抗劑、N乙醯甘露糖胺激酶刺激劑、心營養素-1配位體、白細胞彈性蛋白酶抑制劑、CD40配位體受體拮抗劑、CD40配位體調節劑、IL-17拮抗劑、TLR-2拮抗劑、甘露聚糖結合凝集素絲胺酸蛋白酶-2 (MASP-2)抑制劑、B因子抑制劑、D因子抑制劑及T細胞受體拮抗劑,及其組合。 在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:CTLA-4 (CD152)、PD-1 (CD279)、PDL-1 (CD274)、TIM-3、LAG-3 (CD223)、VISTA、KIR、NKG2A、BTLA、PD-1H、TIGIT、CD96、4-1BB (CD137)、4-1BBL (CD137L)、GARP、CSF-1R、A2AR、CD73、CD47、色胺酸2,3-雙加氧酶(TDO)或吲哚胺2,3雙加氧酶(IDO)之抑制劑,及OX40、GITR、4-1BB、ICOS、STING或CD40之促效劑。 在一些實施例中,該一或多種其他治療劑選自由以下組成之群:CCR1、CCR2、CCR3、CCR4、CCR5、CCR6、CCR7、CCR8、CCR9、CCR10、CCR11、CXCR1、CXCR2、CXCR3、CXCR4、CXCR5、CXCR6、CXCR7、CX3CR1及ChemR23之調節劑。 在一些實施例中,該一或多種其他治療劑選自由皮質類固醇、類固醇、CD20抑制劑及免疫抑制劑組成之群。在一些實施例中,該一或多種其他治療劑為免疫抑制劑。在一些實施例中,該一或多種其他治療劑為皮質類固醇或類固醇。在一些實施例中,該一或多種其他治療劑為CD20抑制劑。在一些實施例中,該一或多種其他治療劑為皮質類固醇或類固醇及免疫抑制劑或CD20抑制劑。在一些實施例中,該一或多種其他治療劑為皮質類固醇或類固醇及免疫抑制劑。在一些實施例中,該一或多種其他治療劑為皮質類固醇或類固醇及CD20抑制劑。 在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:歐比托珠單抗(obinutuzumab)、利妥昔單抗(rituximab)、奧克珠單抗(ocrelizumab)、環磷醯胺、潑尼松(prednisone)、氫化皮質酮、氫化皮質酮乙酸酯、皮質酮乙酸酯、替可的松特戊酸酯(tixocortol pivalate)、潑尼龍(prednisolone)、甲基潑尼龍、曲安奈德(triamcinolone acetonide)、曲安西龍醇(triamcinolone alcohol)、莫米松(mometasone)、安西奈德(amcinonide)、布地奈德(budesonide)、地奈德(desonide)、氟西奈德(fluocinonide)、丙酮化氟新龍(fluocinolone acetonide)、哈西奈德(halcinonide)、倍他米松(betamethasone)、倍他米松磷酸鈉、地塞米松(dexamethasone)、地塞米松磷酸鈉、氟可龍(fluocortolone)、氫化皮質酮-17-戊酸酯、鹵米松(halometasone)、阿氯米松二丙酸酯(alclometasone dipropionate)、倍氯米松(beclomethasone)、倍他米松戊酸酯、倍他米松二丙酸酯、潑尼卡酯(prednicarbate)、氯倍他松-17-丁酸酯(clobetasone-17-butyrate)、氯倍他索-17-丙酸酯(clobetasol-17-propionate)、氟可龍己酸酯、氟可龍特戊酸酯、氟潑尼定乙酸酯(fluprednidene acetate)、氫化皮質酮-17-丁酸酯、氫化皮質酮-17-乙丙酸酯、氫化皮質酮-17-丁丙酸酯、環索奈德(ciclesonide)、潑尼卡酯、GB-0998、益繆格洛(immuglo)、貝格洛瑪(begelomab)、阿法賽特(alefacept)、阿地白介素(aldesleukin)、介維單抗(gevokizumab)、達利珠單抗(daclizumab)、巴利昔單抗(basiliximab)、伊諾莫單抗(inolimomab)、培米諾近(beperminogene perplasmid)、思魯庫單抗(sirukumab)、托西利單抗(tocilizumab)、科薩單抗(clazakizumab)、美泊利單抗(mepolizumab)、芬戈莫德(fingolimod)、帕比司他(panobinostat)、曲西立濱(triciribine)、尼羅替尼(nilotinib)、伊馬替尼(imatinib)、托法替尼(tofacitinib)、莫羅替尼(momelotinib)、皮非替尼(peficitinib)、抑覃西替尼(itacitinib)、英利昔單抗(infliximab)、PEG-bHb-CO、依那西普(etanercept)、依薩佐米(ixazomib)、硼替佐米(bortezomib)、莫羅莫那(muromonab)、奧昔珠單抗(otelixizumab)、胍立莫司(gusperimus)、貝倫妥單抗維多汀(brentuximab vedotin)、硼絲莫德(Ponesimod)、KRP-203、FG-3019、恩利卡生(emricasan)、促皮質素、依魯替尼(ibrutinib)、西瑞斯(cinryze)、康益斯塔(conestat)、甲氧基聚乙二醇-倍他依泊汀(methoxy polyethylene glycol-epoetin beta)、貝利單抗(belimumab)、布里莫德(blisibimod)、阿塞西普(atacicept)、塞利希布(seliciclib)、內卉麗珠單抗(neihulizumab)、依維莫司(everolimus)、西羅莫司(sirolimus)、地尼白介素迪夫托斯(denileukin diftitox)、LMB-2、那他珠單抗(natalizumab)、卡曲地可(catridecacog)、環孢菌素、他克莫司(tacrolimus)、伏環孢素、伏環孢素、康納單抗(canakinumab)、黴酚酸酯、咪唑立賓(mizoribine)、CE-1145、TK-DLI、阿巴西普(abatacept)、貝拉西普(belatacept)、奧美沙坦美度米(olmesartan medoxomil)、斯帕森坦(sparsentan)、TXA-127、BIIB-023、阿侖單抗(alemtuzumab)、噴司他丁(pentostatin)、意托麗珠單抗(itolizumab)、帕利夫明(palifermin)、來氟米特(leflunomide)、PRO-140、森尼韋若(cenicriviroc)、福他替尼(fostamatinib)、安尼福單抗(anifrolumab)、絲法力單抗(sifalimumab)、BAX-069、BG-00011、洛嗎莫德(losmapimod)、QPI-1002、ShigamAbs、TZ-101、F-652、瑞帕銳星(reparixin)、蘭達銳星(ladarixin)、PTX-9908、阿伽尼塞(aganirsen)、APH-703、索塔妥林(sotrastaurin)、索塔妥林、米拉珠單抗(milatuzumab)、SM-101、T-Guard、APG-101、DEX-M74、心營養素-1、替普勒斯坦(tiprelestat)、ASKP-1240、BMS-986004、HPH-116、KD-025、OPN-305、TOL-101、去纖維蛋白多核苷酸、泊利度胺(pomalidomide)、抗胸腺細胞免疫球蛋白(Thymoglobulin)、拉喹莫德(laquinimod)、瑞米特塞-L (remestemcel-L)、馬抗胸腺細胞免疫球蛋白、斯丹標塞(Stempeucel)、LIV-γ、10%奧克塔加(Octagam 10%)、t2c-001、99mTc-塞坦米必(99mTc-sestamibi)、克萊瑞格(Clairyg)、普若索拔(Prosorba)、泊利度胺、拉喹莫德、替利珠單抗(teplizumab)、FCRx、索那替德(solnatide)、福然單抗(foralumab)、ATIR-101、BPX-501、ACP-01、ALLO-ASC-DFU、依貝沙坦+丙帕鍺(irbesartan + propagermanium)、ApoCell、大麻二酚、RGI-2001、乳清酸、抗CD3二價抗體-白喉毒素共軛物、NOX-100及LT-1951。 在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:OMS721、ALN-CC5、ACH-4471、AMY-101、阿卡瑟凝膠(Acthar gel)、CCX354、CCX9588、CCX140、CCX872、CCX598、CCX6239、CCX9664、CCX2553、CCX 2991、CCX282、CCX025、CCX507、CCX430、CCX765、CCX224、CCX662、CCX650、CCX832、派立珠單抗(pembrolizumab)、納武單抗(nivolumab)、IBI-308、mDX-400、BGB-108、MEDI-0680、SHR-1210、PF-06801591、PDR-001、GB-226、STI-1110、德瓦魯單抗(durvalumab)、阿特唑單抗(atezolizumab)、艾維路單抗(avelumab)、BMS-936559、ALN-PDL、TSR-042、KD-033、CA-170、STI-1014、KY-1003、CA-327及CD4+CD25+調節性T細胞,及其組合。 在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:歐比托珠單抗、利妥昔單抗、奧克珠單抗、環磷醯胺、潑尼松、氫化皮質酮、氫化皮質酮乙酸酯、皮質酮乙酸酯、替可的松特戊酸酯、潑尼龍、甲基潑尼龍、曲安奈德、曲安西龍醇、莫米松、安西奈德、布地奈德、地奈德、氟西奈德、丙酮化氟新龍、哈西奈德、倍他米松、倍他米松磷酸鈉、地塞米松、地塞米松磷酸鈉、氟可龍、氫化皮質酮-17-戊酸酯、鹵米松、阿氯米松二丙酸酯、倍氯米松、倍他米松戊酸酯、倍他米松二丙酸酯、潑尼卡酯、氯倍他松-17-丁酸酯、氯倍他索-17-丙酸酯、氟可龍己酸酯、氟可龍特戊酸酯、氟潑尼定乙酸酯、氫化皮質酮-17-丁酸酯、氫化皮質酮-17-乙丙酸酯、氫化皮質酮-17-丁丙酸酯、環索奈德及潑尼卡酯。 在一些實施例中,該一或多種其他治療劑為利妥昔單抗或環磷醯胺。在一些實施例中,該一或多種其他治療劑為利妥昔單抗。在一些實施例中,該一或多種其他治療劑為環磷醯胺。在一些實施例中,該一或多種其他治療劑為潑尼松。在一些實施例中,該一或多種其他治療劑為利妥昔單抗或環磷醯胺及潑尼松。IV. 治療藉由 C5A 調節之 疾病及病症之方法
本發明之化合物可用於在活體內生成為C5a受體之促效劑、(較佳地)拮抗劑、偏促效劑、逆向促效劑之活性代謝物。在一個實施例中,本發明之化合物可用於生成為C5aR拮抗劑之活性代謝物,以在活體內抑制C5a受體配位體(例如,C5a)與C5a受體之結合。 較佳地,由本發明之化合物所產生的與受體接觸之C5a受體調節劑的量應足以抑制C5a結合至C5a受體。 在另一實施例中,本發明化合物進一步可用於治療罹患響應於C5a受體調節之病況的患者。如本文所使用,術語「治療(treating/treatment)」涵蓋疾病改變治療及對症治療兩者,其中之任一者可為預防性的(亦即,在症狀發作之前,以便預防、延遲或降低症狀嚴重程度)或治療性的(亦即,在症狀發作之後,以便降低症狀之嚴重程度及/或持續時間)。如本文所使用,若調節C5a受體活性使得C5a受體之不當活性降低,則認為病況「響應於C5a受體調節」。如本文所使用,術語「患者」包括具有如本文所描述之劑量的靈長類動物(尤其人類)、家養伴侶動物(諸如狗、貓、馬及其類似動物)及家畜(諸如牛、豬、羊及其類似動物)。 可藉由 C5a 調節治療的病況 : 自體免疫病症
--例如,類風濕性關節炎、全身性紅斑性狼瘡症、格-巴二氏症候群(Guillain-Barre syndrome)、胰臟炎、狼瘡性腎炎、狼瘡性絲球體腎炎、牛皮癬、克隆氏病(Crohn's disease)、脈管炎、大腸急躁症候群、皮肌炎、多發性硬化症、支氣管哮喘、天疱瘡、類天疱瘡、硬皮病、重症肌無力、自體免疫溶血性及血小板減少性病況、aHUS (非典型性溶血性尿毒症症候群)、古德巴士德氏症候群(Goodpasture's syndrome) (及相關聯絲球體腎炎及肺出血)、免疫性血管炎、組織移植物排斥反應、經移植器官之超急性排斥反應及其類似病症。發炎性病症及相關病況
--例如,嗜中性白血球減少症、敗血症、敗血性休克、阿茲海默氏病(Alzheimer's disease)、多發性硬化症、中風、發炎性腸病(IBD)、年齡相關黃斑變性(AMD,濕型及乾型兩者)、與重度燒傷相關的發炎、肺臟損傷及缺血-再灌注損傷、骨關節炎以及急性(成人)呼吸窘迫症候群(ARDS)、慢性肺部阻塞性病症(COPD)、全身性發炎性反應症候群(SIRS)、異位性皮炎、牛皮癬、慢性蕁麻疹及多器官功能障礙症候群(MODS)。亦包括與胰島素依賴型糖尿病相關的病理性後遺症(包括糖尿病性視網膜病變)、狼瘡腎病、海曼腎炎(Heyman nephritis)、膜性腎炎及其他形式之絲球體腎炎、IGA腎病、接觸敏感性反應及由血液與可使得補體活化之人造表面接觸(如例如在血液之體外循環期間所進行(例如在血液透析期間或經由心臟-肺臟機器,例如與諸如冠狀動脈繞通移植或心臟瓣膜置換之血管手術結合))引起或與其他人造血管或容器表面(例如心室輔助裝置、人造心臟機器、輸血導管、儲血袋、血漿清除術、血小板清除術及其類似物)接觸相關的發炎。亦包括與缺血/再灌注損傷相關的疾病,諸如由移植(包括實體器官移植)引起的彼等疾病,及症候群,諸如缺血性再灌注損傷、缺血性結腸炎及心臟缺血。本發明之化合物亦可適用於治療年齡相關黃斑變性(Hageman等人,P.N.A.S. 102:
7227-7232, 2005)。心血管及腦血管病症
--例如心肌梗塞、冠狀動脈血栓、血管閉塞、手術後血管再閉塞、動脈粥樣硬化、創傷性中樞神經系統損傷及缺血性心臟病。在一個實施例中,可向處於心肌梗塞或血栓風險下之患者(亦即,識別出一或多個心肌梗塞或血栓之風險因素的患者,該一或多個風險因素諸如(但不限於)肥胖、吸菸、高血壓、高膽固醇血症、心肌梗塞或血栓之先前或遺傳病史)投與有效量之本發明化合物以降低心肌梗塞或血栓之風險。血管炎疾病
--血管炎疾病之特徵為血管發炎。白血球浸潤導致血管壁受損,且咸信補體路徑在引發白細胞遷移以及發炎部位處顯現之所得損害方面起主要作用(Vasculitis,第二版,Ball and Bridges編,牛津大學出版社,第47-53頁,2008)。本發明提供之化合物可用於治療ANCA血管炎(抗嗜中性白血球細胞質自體抗體血管炎)。本發明提供之化合物可用於治療白血球破碎性血管炎、蕁麻疹血管炎、韋格納氏肉芽腫病(Wegener's granulomatosis)、顯微鏡下多血管炎、丘-施二氏症候群(Churg-Strauss syndrome)、亨-舍二氏紫斑病(Henoch-Schonlein purpura)、結節性多動脈炎、急進性絲球體腎炎(RPGN)、冷球蛋白血症、巨大細胞動脈炎(GCA)、貝切特氏疾病(Behcet's disease)及高安氏動脈炎(Takayasu's arteritis) (TAK)。HIV 感染及 AIDS
--本文提供之C5a受體調節劑可用於抑制HIV感染、延遲AIDS進展或降低症狀或HIV感染及AIDS之嚴重程度。神經退化性病症及相關疾病
--在其他態樣內,本文所提供之C5a拮抗劑可用於治療阿茲海默氏病、多發性硬化症及與心肺繞通手術及相關程序相關的認知功能減退。癌症 ¾
本文提供之C5a拮抗劑亦可用於治療個體中之癌症及癌前病況。可治療之特定癌症包括(但不限於)黑色素瘤、肺癌、淋巴瘤、肉瘤、癌瘤及混合型腫瘤。可根據本發明治療之例示性病況包括纖維肉瘤、脂肪肉瘤、軟骨肉瘤、骨原性肉瘤、血管肉瘤、淋巴管肉瘤、滑膜瘤、間皮瘤、腦膜瘤、白血病、淋巴瘤、平滑肌肉瘤、橫紋肌肉瘤、鱗狀細胞癌、基底細胞癌、腺癌、乳突瘤、囊腺癌、支氣管癌、黑色素瘤、腎細胞癌、肝細胞癌、移行細胞癌、絨膜癌、精細胞瘤、胚胎性瘤、威爾姆斯瘤(wilm's tumor)、多形性腺瘤、肝細胞乳頭狀瘤、腎源性小管性腺瘤、囊腺瘤、乳頭狀瘤、腺瘤、平滑肌瘤、橫紋肌瘤、血管瘤、淋巴管瘤、骨瘤、軟骨瘤、脂瘤及纖維瘤。在一些實施例中,疾病或病症選自由以下各者組成之群:神經膠母細胞瘤、食道瘤、鼻咽癌、葡萄膜黑色素瘤、淋巴瘤、淋巴性淋巴瘤、早期CNS淋巴瘤、T細胞淋巴瘤、彌漫性大B細胞淋巴瘤、早期縱隔大B細胞淋巴瘤、前列腺癌、去勢耐藥性前列腺癌、慢性骨髓細胞性白血病、卡堡氏肉瘤纖維肉瘤(Kaposi's sarcoma fibrosarcoma)、脂肪肉瘤、軟骨肉瘤、骨原性肉瘤、血管肉瘤、淋巴管肉瘤、滑膜瘤、腦膜瘤、平滑肌肉瘤、橫紋肌肉瘤、軟組織瘤、肉瘤、敗血症、膽管腫瘤、基底細胞癌、胸腺瘤、甲狀腺癌、副甲狀腺腺體癌、子宮癌、腎上腺腺體癌、肝感染、梅克爾細胞癌(Merkel cell carcinoma)、神經瘤、濾泡性中心淋巴瘤、結腸癌、霍奇金氏疾病(Hodgkin's disease)、非霍奇金氏淋巴瘤、白血病、慢性或急性白血病(包括急性骨髓白血病、慢性骨髓性白血病、急性淋巴母細胞白血病、慢性淋巴球性白血病)、多發性骨髓瘤、卵巢瘤、骨髓發育不良症候群、皮膚或眼內惡性黑色素瘤、腎細胞癌、小細胞肺癌、肺癌、間皮瘤、乳癌、鱗狀非小細胞肺癌(SCLC)、非鱗狀NSCLC、結腸直腸癌、卵巢癌、胃癌、肝細胞癌、胰臟癌瘤、胰臟癌、胰管腺癌、頭部及頸部鱗狀細胞癌、頭部或頸部癌症、胃腸道、胃癌、骨癌、皮膚癌、直腸癌、肛門區癌、睪丸癌、輸卵管癌、子宮內膜癌、宮頸癌、陰道癌、外陰癌、食道癌、小腸癌、內分泌系統癌、尿道癌、陰莖癌、膀胱癌、腎癌、輸尿管癌、腎盂癌、中樞神經系統(CNS)贅瘤、腫瘤血管生成、脊柱腫瘤、腦幹神經膠質瘤、垂體腺瘤、表皮樣癌、石棉沉著症及癌瘤。 在另一實施例中,本發明之化合物適用於治療順鉑誘發型腎毒性。在此實施例中,化合物治療能夠減輕藉由惡性腫瘤之順鉑化學療法所誘發之腎毒性(Hao Pan等人,Am J Physiol Renal Physiol
,296, F496-504, 2009)。 在本發明之一個實施例中,本發明之化合物可用於治療選自由以下各者組成之群的疾病:敗血症(及相關病症)、COPD、類風濕性關節炎、狼瘡性腎炎及多發性硬化症。 本文提供一種治療罹患或易患涉及C5a受體之病理性活化之疾病或病症的人類的方法,其包含向哺乳動物投與治療有效量之本發明化合物或其醫藥組合物。 本文提供一種抑制C5a受體調節之細胞趨化性,其包含用本發明之化合物之活性代謝物的C5a受體調節量來接觸哺乳動物的白血細胞。 在一些實施例中,疾病或病症為發炎疾病或病症、心血管或腦血管病症、自體免疫疾病或致癌性疾病或病症。 在一些實施例中,疾病或病症選自由以下各者組成之群:嗜中性白血球減少症、嗜中性白血球增多症、C3-腎絲球病變、C3-絲球體腎炎、密度沈積病、膜增生性絲球體腎炎、川崎病(Kawasaki disease)、敗血症、敗血性休克、溶血性尿毒症症候群、非典型性溶血性尿毒症症候群(aHUS)、阿茲海默氏病、多發性硬化症、中風、發炎性腸病、慢性阻塞性肺疾病、與燒傷相關的發炎、肺損傷、骨關節炎、異位性皮炎、慢性蕁麻疹、缺血-再灌注損傷、急性呼吸窘迫症候群、全身性發炎反應症候群、多器官功能障礙症候群、葡萄膜炎、組織移植物排斥反應、經移植器官之超急性排斥反應、心肌梗塞、冠狀動脈血栓、血管閉塞、手術後血管再閉塞、動脈粥樣硬化、息肉狀脈絡膜血管病變、創傷性中樞神經系統損傷、缺血性心臟病、類風濕性關節炎、全身性紅斑性狼瘡症、格-巴二氏症候群、胰臟炎、狼瘡性腎炎、狼瘡性絲球體腎炎、牛皮癬、克隆氏病、血管炎、ANCA血管炎、大腸急躁症、皮肌炎、多發性硬化症、支氣管哮喘、天疱瘡、類天疱瘡、硬皮病、重症肌無力、自體免疫溶血性及血小板減少性病況、古德巴士德氏症候群、免疫血管炎、移植物抗宿主疾病、陣發性夜間血紅素尿症、休格連氏症候群(Sjoegrens syndrome)、胰島素依賴型糖尿病、狼瘡性腎病變、海曼腎炎、膜性腎炎、絲球體腎炎、IGA腎病變、膜增生性絲球體腎炎、抗磷脂症候群、年齡相關黃斑變性、乾式年齡相關黃斑變性、濕式年齡相關黃斑變性、運動神經元疾病、接觸性敏感性反應及由血液與人造表面接觸所引起之發炎。 在一些實施例中,疾病或病症係選自由以下各者組成之群:嗜中性白血球減少症、嗜中性白血球增多症、C3-腎絲球病變、C3-絲球體腎炎、密度沈積病、膜增生性絲球體腎炎、川崎病、溶血性尿毒症症候群、非典型性溶血性尿毒症症候群(aHUS)、組織移植物排斥反應、經移植器官之超急性排斥反應、類風濕性關節炎、全身性紅斑性狼瘡症、狼瘡性腎炎、狼瘡性絲球體腎炎、血管炎、ANCA血管炎、自體免疫溶血性及血小板減少性病況、免疫血管炎、移植物抗宿主疾病、狼瘡性腎病變、海曼腎炎、膜性腎炎、絲球體腎炎、IGA腎病變、膜增生性及絲球體腎炎。 在一些實施例中,疾病或病症選自由以下各者組成之群:黑色素瘤、肺癌、淋巴瘤、肉瘤、癌瘤、纖維肉瘤、脂肪肉瘤、軟骨肉瘤、骨原性肉瘤、血管肉瘤、淋巴管肉瘤、滑膜瘤、間皮瘤、腦膜瘤、白血病、淋巴瘤、平滑肌肉瘤、橫紋肌肉瘤、鱗狀細胞癌、基底細胞癌、腺癌、乳頭狀瘤、囊腺癌、支氣管癌、腎細胞癌、肝細胞癌、移行細胞癌、絨膜癌、精細胞癌、胚胎性瘤、威爾姆斯瘤、多形性腺瘤、肝細胞乳頭狀瘤、腎源性小管性腺瘤、囊腺瘤、乳頭瘤、腺瘤、平滑肌瘤、橫紋肌瘤、血管瘤、淋巴管瘤、骨瘤、軟骨瘤、脂肪瘤及纖維瘤。在一些實施例中,疾病或病症選自由以下各者組成之群:神經膠母細胞瘤、食道瘤、鼻咽癌、葡萄膜黑色素瘤、淋巴瘤、淋巴性淋巴瘤、早期CNS淋巴瘤、T細胞淋巴瘤、彌漫性大B細胞淋巴瘤、早期縱隔大B細胞淋巴瘤、前列腺癌、去勢耐藥性前列腺癌、慢性骨髓細胞性白血病、卡堡氏肉瘤纖維肉瘤、脂肪肉瘤、軟骨肉瘤、骨原性肉瘤、血管肉瘤、淋巴管肉瘤、滑膜瘤、腦膜瘤、平滑肌肉瘤、橫紋肌肉瘤、軟組織瘤、肉瘤、敗血症、膽管腫瘤、基底細胞癌、胸腺瘤、甲狀腺癌、副甲狀腺腺體癌、子宮癌、腎上腺腺體癌、肝感染、梅克爾細胞癌、神經瘤、濾泡性中心淋巴瘤、結腸癌、霍奇金氏疾病、非霍奇金氏淋巴瘤、白血病、慢性或急性白血病(包括急性骨髓白血病、慢性骨髓性白血病、急性淋巴母細胞白血病、慢性淋巴球性白血病)、多發性骨髓瘤、卵巢瘤、骨髓發育不良症候群、皮膚或眼內惡性黑色素瘤、腎細胞癌、小細胞肺癌、肺癌、間皮瘤、乳癌、鱗狀非小細胞肺癌(SCLC)、非鱗狀NSCLC、結腸直腸癌、卵巢癌、胃癌、肝細胞癌、胰臟癌瘤、胰臟癌、胰管腺癌、頭部及頸部鱗狀細胞癌、頭部或頸部癌症、胃腸道、胃癌、骨癌、皮膚癌、直腸癌、肛門區癌、睪丸癌、輸卵管癌、子宮內膜癌、宮頸癌、陰道癌、外陰癌、食道癌、小腸癌、內分泌系統癌、尿道癌、陰莖癌、膀胱癌、腎癌、輸尿管癌、腎盂癌、中樞神經系統(CNS)贅瘤、腫瘤血管生成、脊柱腫瘤、腦幹神經膠質瘤、垂體腺瘤、表皮樣癌、石棉沉著症及癌瘤。 在一些實施例中,治療方法進一步包含向人類投與治療有效量之一或多種其他治療劑。在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:皮質類固醇、類固醇、免疫抑制劑、免疫球蛋白G促效劑、二肽基肽酶IV抑制劑、淋巴細胞功能抗原-3受體拮抗劑、介白素-2配位體、介白素-1 β配位體抑制劑、IL-2受體α次單位抑制劑、HGF基因刺激劑、IL-6拮抗劑、IL-5拮抗劑、α 1抗胰蛋白酶刺激劑、類大麻鹼受體拮抗劑、組蛋白脫乙醯基酶抑制劑、AKT蛋白激酶抑制劑、CD20抑制劑、Abl酪胺酸激酶抑制劑、JAK酪胺酸激酶抑制劑、TNF α配位體抑制劑、血紅蛋白調節劑、TNF拮抗劑、蛋白酶體抑制劑、CD3調節劑、Hsp 70家族抑制劑、免疫球蛋白促效劑、CD30拮抗劑、微管蛋白拮抗劑、神經鞘胺醇-1-磷酸酯受體-1促效劑、結締組織生長因子配位體抑制劑、卡斯蛋白酶抑制劑、促腎上腺皮質激素配位體、Btk酪胺酸激酶抑制劑、補體C1s子組分抑制劑、紅血球生成素受體促效劑、B-淋巴細胞刺激子配位體抑制劑、週期蛋白依賴型激酶-2抑制劑、P-選擇素醣蛋白配位體-1刺激劑、mTOR抑制劑、延長因子2抑制劑、細胞黏附分子抑制劑、XIII因子促效劑、鈣調神經磷酸酶抑制劑、免疫球蛋白G1促效劑、肌核苷單磷酸去氫酶抑制劑、補體C1s子組分抑制劑、胸苷激酶調節劑、細胞毒性T-淋巴細胞蛋白-4調節劑、血管緊張素II受體拮抗劑、血管緊張素II受體調節劑、TNF超家族受體12A拮抗劑、CD52拮抗劑、腺苷脫胺酶抑制劑、T細胞分化抗原CD6抑制劑、FGF-7配位體、二氫乳清酸去氫酶抑制劑、CCR5趨化介素拮抗劑、CCR2趨化介素拮抗劑、Syk酪胺酸激酶抑制劑、I型干擾素受體拮抗劑、α干擾素配位體抑制劑、巨噬細胞遷移抑制因子抑制劑、整合素α-V/β-6拮抗劑、半胱胺酸蛋白酶刺激劑、p38 MAP激酶抑制劑、TP53基因抑制劑、志賀樣毒素I抑制劑、海藻糖基轉移酶6刺激劑、介白素22配位體、CXCR1趨化介素拮抗劑、CXCR4趨化介素拮抗劑、IRS1基因抑制劑、蛋白激酶C刺激劑、蛋白激酶C α抑制劑、CD74拮抗劑、免疫球蛋白γ Fc受體IIB拮抗劑、T細胞抗原CD7抑制劑、CD95拮抗劑、N乙醯甘露糖胺激酶刺激劑、心營養素-1配位體、白細胞彈性蛋白酶抑制劑、CD40配位體受體拮抗劑、CD40配位體調節劑、IL-17拮抗劑、TLR-2拮抗劑及T細胞受體拮抗劑,及其組合。在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:甘露聚糖結合凝集素絲胺酸蛋白酶-2 (MASP-2)抑制劑、B因子抑制劑、D因子抑制劑。 在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:CTLA-4 (CD152)、PD-1 (CD279)、PDL-1 (CD274)、TIM-3、LAG-3 (CD223)、VISTA、KIR、NKG2A、BTLA、PD-1H、TIGIT、CD96、4-1BB (CD137)、4-1BBL (CD137L)、GARP、CSF-1R、A2AR、CD73、CD47、色胺酸2,3-雙加氧酶(TDO)或吲哚胺2,3雙加氧酶(IDO)之抑制劑,及OX40、GITR、4-1BB、ICOS、STING或CD40之促效劑。 在一些實施例中,該一或多種其他治療劑選自由以下組成之群:CCR1、CCR2、CCR3、CCR4、CCR5、CCR6、CCR7、CCR8、CCR9、CCR10、CCR11、CXCR1、CXCR2、CXCR3、CXCR4、CXCR5、CXCR6、CXCR7、CX3CR1及ChemR23之調節劑。 在一些實施例中,該一或多種其他治療劑選自由皮質類固醇、類固醇、CD20抑制劑及免疫抑制劑組成之群。在一些實施例中,該一或多種其他治療劑為免疫抑制劑。在一些實施例中,該一或多種其他治療劑為皮質類固醇或類固醇。在一些實施例中,該一或多種其他治療劑為CD20抑制劑。在一些實施例中,該一或多種其他治療劑為皮質類固醇或類固醇及免疫抑制劑或CD20抑制劑。在一些實施例中,該一或多種其他治療劑為皮質類固醇或類固醇及免疫抑制劑。在一些實施例中,該一或多種其他治療劑為皮質類固醇或類固醇及CD20抑制劑。 在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:歐比托珠單抗、利妥昔單抗、奧克珠單抗、環磷醯胺、潑尼松、氫化皮質酮、氫化皮質酮乙酸酯、皮質酮乙酸酯、替可的松特戊酸酯、潑尼龍、甲基潑尼龍、曲安奈德、曲安西龍醇、莫米松、安西奈德、布地奈德、地奈德、氟西奈德、丙酮化氟新龍、哈西奈德、倍他米松、倍他米松磷酸鈉、地塞米松、地塞米松磷酸鈉、氟可龍、氫化皮質酮-17-戊酸酯、鹵米松、阿氯米松二丙酸酯、倍氯米松、倍他米松戊酸酯、倍他米松二丙酸酯、潑尼卡酯、氯倍他松-17-丁酸酯、氯倍他索-17-丙酸酯、氟可龍己酸酯、氟可龍特戊酸酯、氟潑尼定乙酸酯、氫化皮質酮-17-丁酸酯、氫化皮質酮-17-乙丙酸酯、氫化皮質酮-17-丁丙酸酯、環索奈德及潑尼卡酯、GB-0998、益繆格洛、貝格洛瑪、阿法賽特、阿地白介素、介維單抗、達利珠單抗、巴利昔單抗、伊諾莫單抗、培米諾近、思魯庫單抗、托西利單抗、科薩單抗、美泊利單抗、芬戈莫德、帕比司他、曲西立濱、尼羅替尼、伊馬替尼、托法替尼、莫羅替尼、皮非替尼、抑覃西替尼、英利昔單抗、PEG-bHb-CO、依那西普、依薩佐米、硼替佐米、莫羅莫那、奧昔珠單抗、胍立莫司、貝倫妥單抗維多汀、硼絲莫德、KRP-203、FG-3019、恩利卡生、促皮質素、依魯替尼、西瑞斯、康益斯塔、甲氧基聚乙二醇-倍他依泊汀、貝利單抗、布里莫德、阿塞西普、塞利希布、內卉麗珠單抗、依維莫司、西羅莫司、地尼白介素迪夫托斯、LMB-2、那他珠單抗、卡曲地可、環孢菌素、他克莫司、伏環孢素、伏環孢素、康納單抗、黴酚酸酯、咪唑立賓、CE-1145、TK-DLI、阿巴西普、貝拉西普、奧美沙坦美度米、斯帕森坦、TXA-127、BIIB-023、阿侖單抗、噴司他丁、意托麗珠單抗、帕利夫明、來氟米特、PRO-140、森尼韋若、福他替尼、安尼福單抗、絲法力單抗、BAX-069、BG-00011、洛嗎莫德、QPI-1002、ShigamAbs、TZ-101、F-652、瑞帕銳星、蘭達銳星、PTX-9908、阿伽尼塞、APH-703、索塔妥林、索塔妥林、米拉珠單抗、SM-101、T-Guard、APG-101、DEX-M74、心營養素-1、替普勒斯坦、ASKP-1240、BMS-986004、HPH-116、KD-025、OPN-305、TOL-101、去纖維蛋白多核苷酸、泊利度胺、抗胸腺細胞免疫球蛋白、拉喹莫德、瑞米特塞-L、馬抗胸腺細胞免疫球蛋白、斯丹標塞、LIV-γ、10%奧克塔加、t2c-001、99mTc-塞坦米必、克萊瑞格、普若索拔、泊利度胺、拉喹莫德、替利珠單抗、FCRx、索那替德、福然單抗、ATIR-101、BPX-501、ACP-01、ALLO-ASC-DFU、依貝沙坦+丙帕鍺、ApoCell、大麻二酚、RGI-2001、薩瑞停、抗CD3二價抗體-白喉毒素共軛物、NOX-100及LT-1951。在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:OMS721、ALN-CC5、ACH-4471、AMY-101、阿卡瑟凝膠、CCX354、CCX9588、CCX140、CCX872、CCX598、CCX6239、CCX9664、CCX2553、CCX 2991、CCX282、CCX025、CCX507、CCX430、CCX765、CCX224、CCX662、CCX650、CCX832、派立珠單抗、納武單抗、IBI-308、mDX-400、BGB-108、MEDI-0680、SHR-1210、PF-06801591、PDR-001、GB-226、STI-1110、德瓦魯單抗、阿特唑單抗、艾維路單抗、BMS-936559、ALN-PDL、TSR-042、KD-033、CA-170、STI-1014、KY-1003、CA-327及CD4+CD25+調節性T細胞,及其組合。 在一些實施例中,該一或多種其他治療劑選自由以下各者組成之群:歐比托珠單抗、利妥昔單抗、奧克珠單抗、環磷醯胺、潑尼松、氫化皮質酮、氫化皮質酮乙酸酯、皮質酮乙酸酯、替可的松特戊酸酯、潑尼龍、甲基潑尼龍、曲安奈德、曲安西龍醇、莫米松、安西奈德、布地奈德、地奈德、氟西奈德、丙酮化氟新龍、哈西奈德、倍他米松、倍他米松磷酸鈉、地塞米松、地塞米松磷酸鈉、氟可龍、氫化皮質酮-17-戊酸酯、鹵米松、阿氯米松二丙酸酯、倍氯米松、倍他米松戊酸酯、倍他米松二丙酸酯、潑尼卡酯、氯倍他松-17-丁酸酯、氯倍他索-17-丙酸酯、氟可龍己酸酯、氟可龍特戊酸酯、氟潑尼定乙酸酯、氫化皮質酮-17-丁酸酯、氫化皮質酮-17-乙丙酸酯、氫化皮質酮-17-丁丙酸酯、環索奈德及潑尼卡酯。 在一些實施例中,該一或多種其他治療劑為利妥昔單抗或環磷醯胺。在一些實施例中,該一或多種其他治療劑為利妥昔單抗。在一些實施例中,該一或多種其他治療劑為環磷醯胺。在一些實施例中,該一或多種其他治療劑為潑尼松。在一些實施例中,該一或多種其他治療劑為利妥昔單抗或環磷醯胺及潑尼松。 本文所提供之治療方法一般包括向患者投與有效量之一或多種本文所提供之化合物。合適之患者包括罹患或易患(亦即,預防性治療)本文中所識別之病症或疾病的彼等患者。對於如本文所描述之治療,典型的患者包括哺乳動物,詳言之,靈長類動物,尤其人類。其他適合之患者包括家養伴侶動物,諸如狗、貓、馬及其類似動物;或家畜動物,諸如牛、豬、羊及其類似動物。 一般而言,本文所提供之治療方法包含向患者投與有效量之化合物(一或多種本文所提供之化合物)。在一些實施例中,本發明之化合物經靜脈內、經口或經表面投與給患者(例如,人類)。在一較佳實施例中,本發明之化合物較佳經靜脈內投與給患者(例如,人類)。有效量可為足以調節C5a受體活性之量及/或足以降低或緩解患者所呈現之症狀之量。較佳地,投與量足以產生足夠高之其活性代謝物之血漿濃度,以可檢測地在活體外抑制白血球(例如,嗜中性白血球)趨化性。治療方案可視所使用之化合物及欲治療之特定病況而變化;對於大多數病症之治療,每天4次或小於4次之投與頻率為較佳的。一般而言,每天2次之給藥方案為更佳的,其中一日一次給藥尤其較佳。然而,應理解,任何特定患者之特定劑量水準及治療方案將視多種因素而定,包括所採用之特定化合物之活性、年齡、體重、一般健康狀況、性別、飲食、投與時間、投與途徑、分泌速率、藥物組合(亦即,向患者投與之其他藥物)及經歷療法之特定疾病之嚴重程度以及開處方醫師之判斷。一般而言,使用足以提供有效療法之最小劑量為較佳的。一般可針對治療有效性,使用適用於所治療或預防之病況之醫學或獸醫學準則,來監測患者。 大約每天每公斤體重約0.1 mg至約140 mg之劑量水準適用於治療或預防涉及病原性C5a活性之病況(每天每個人類患者約0.5 mg至約7 g)。可與載劑材料組合產生單一劑型之本發明之化合物的量將視所治療之主體及特定投與模式而變化。單位劑型將一般含有約1 mg至約500 mg之間的活性成份。對於經口、經皮、靜脈內、肌肉內或皮下投與之化合物,較佳的是投與足夠量的化合物以達到5 ng (奈克)/mL至10 μg (微克)/mL血清之血清濃度,更佳應投與足夠的化合物以達到20 ng/ml至1 μg/ml血清之血清濃度,最佳應投與足夠的化合物以達到50 ng/ml至200 ng/ml血清之血清濃度。為直接注射至滑膜(用於治療關節炎)中,應投與足夠的化合物以達到約1微莫耳之局部濃度。 劑量頻率亦可視所使用之化合物及所治療之特定疾病而變化。然而,對於大多數病症之治療而言,每天4次、每天三次或小於三次之給藥方案為較佳的,其中每天一次或每天2次之給藥方案尤其較佳。然而,應理解,任何特定患者之特定劑量水準將視多種因素而定,包括所採用之特定化合物之活性、年齡、體重、一般健康狀況、性別、飲食、投與時間、投與途徑及分泌速率、藥物組合(亦即,向患者投與之其他藥物)、經歷療法之特定疾病之嚴重程度及其他因素,包括開處方醫師之判斷。套組及包裝
術語「套組」及「醫藥學上之套組」係指在一或多個合適之容器中包含一或多種醫藥組合物及其使用說明書的商購套組或包裝。在一個實施例中,提供包含本發明之化合物或其醫藥學上可接受之鹽及其投與說明書的套組。在一個實施例中,提供包含與一或多種(例如,一種、兩種、三種、一或兩種或一至三種)其他治療劑組合之本發明化合物或其醫藥學上可接受之鹽及其投與說明書的套組。 在一個實施例中,將本發明之化合物調配成包裝在單一包裝中之投藥單位。該單一包裝涵蓋(但不限於)瓶、防止兒童開啟的瓶、安瓿及套管。在一個實施例中,將本發明之化合物及視情況選用之其他治療劑調配成投藥單位,且每一單一投藥單位單獨地包裝在單一包裝中。此單獨包裝之單位可含有呈任何形式(包括但不限於液體形式、固體形式、粉末形式、顆粒形式、發泡粉末或錠劑、硬性或軟性膠囊、乳液、懸浮液、糖漿、栓劑、錠劑、糖衣錠、口含劑、溶液、口腔貼片、薄膜、口服凝膠、咀嚼錠劑、口嚼錠)之醫藥組合物及一次性注射器。此單獨包裝之單位可組合於由紙、卡板、紙板、金屬箔及塑膠箔(例如泡殼包裝)中之一或多者製成的包裝中。一或多個投藥單位可一天投與一次或若干次。一或多個投藥單位可一天投與三次。一或多個投藥單位可一天投與兩次。一或多個投藥單位可在第一天投與且一或多個投藥單位可在隨後若干天投與。V. 實例
提供以下實例以進行說明,而非限制所主張之發明。 以下所使用之試劑及溶劑可獲自市售來源,諸如Aldrich Chemical Co. (Milwaukee, Wisconsin, USA)。在Varian Mercury 400 MHz NMR光譜儀上記錄1
H-NMR光譜。相對於TMS提供顯著峰且按以下順序表列:多重性(s,單重峰;d,二重峰;t,三重峰;q,四重峰;m,多重峰)及質子數。質譜分析結果報導為質量與電荷之比率,隨後為各離子之相對豐度(在括弧中)。在實例中,針對含有最常見原子同位素之M+H (或如所述,M-H)離子報導單一m/e值。在所有情況下,同位素圖案對應於預期式。在Hewlett-Packard MSD電噴霧質譜儀上,使用用於樣品遞送之HP1100 HPLC來進行電噴霧電離(ESI)質譜分析。通常,使分析物以0.1 mg/mL溶解於甲醇中且用遞送溶劑輸注1微升至質譜儀中,其在100道爾頓與1500道爾頓之間進行掃描。可在陽性ESI模式中,使用具有1%甲酸之乙腈/水作為遞送溶劑來分析所有化合物。亦可在陰性ESI模式中,使用含2 mM NH4
OAc之乙腈/水作為遞送系統來分析下文所提供之化合物。 在實例中及在本發明之整個說明書中使用以下縮寫: EtOH: 乙醇 EtONa: 乙醇鈉 THF: 四氫呋喃 TLC: 薄層層析法 MeOH: 甲醇 可如下文所描述,使用熟習此項技術者已知之多種反應物來合成本發明範疇內之化合物。熟習此項技術者亦將認識到,可採用替代方法來合成本發明之目標化合物,且在本文件之內文內描述之方法並非窮盡性的,而是提供相關化合物之廣泛可應用且實際的途徑。 本專利中主張之某些分子可以不同對映異構體及非對映異構體形式存在且主張此等化合物之所有此類變體。 用於合成本文中之關鍵化合物之實驗程序的詳細描述產生藉由鑑別其之物理資料以及與其相關的結構繪圖所描述之分子。 熟習此項技術者亦將認識到,在有機化學中之標準處理程序期間,頻繁使用酸及鹼。在本專利內所描述之實驗程序期間,若母體化合物之鹽具有所需固有酸性或鹼性,則有時產生母體化合物之鹽。實例 1 : (2R
,3S
)-2-[4-[ 環戊基 -[2-( 二甲胺基 ) 乙醯基 ] 胺基 ] 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 )-N
-[4- 甲基 -3-( 三氟甲基 ) 苯基 ] 哌啶 -3- 甲醯胺之合成 步驟a:在室溫下,向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(100 mg,0.17 mmol)於無水二氯甲烷(5 mL)中之攪拌溶液中添加吡啶(0.2 mL,0.26 mmol)及2-氯乙醯氯(100 µL,0.34 mmol)。在室溫下攪拌混合物1 h。反應完成後,反應混合物用CH2
Cl2
稀釋,用1N HCl洗滌且隨後用飽和NaHCO3
水溶液洗滌,經Na2
SO4
乾燥且在真空中濃縮。粗產物直接用於下一步驟中而不經任何進一步純化。 步驟b:將來自以上反應之粗產物溶解於四氫呋喃(5 mL)及H2
O (1 mL)中,接著添加含K2
CO3
(50 mg,0.36 mmol)及1M二甲胺之THF (0.6 mL,0.6 mmol)。在rt下攪拌混合物隔夜,且隨後在60℃下攪拌2 h。反應完成後,用EtOAc稀釋,用水洗滌且經Na2
SO4
乾燥並且在真空中濃縮。粗化合物藉由矽膠層析法(首先為10-100%乙酸乙酯/己烷,且接著為0-15% MeOH/EtOAc)純化,得到(2R
,3S
)-2-[4-[環戊基-[2-(二甲胺基)乙醯基]胺基]苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺。MS:C37
H42
F4
N4
O3
[M + H]+
之(ES)m/z
計算值為667.3,實驗值為667.8。實例 2 : (2R
,3S
)-2-[4-[(2- 胺基乙醯基 )- 環戊基 - 胺基 ] 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 )-N
-[4- 甲基 -3-( 三氟甲基 ) 苯基 ] 哌啶 -3- 甲醯胺之合成 與實例1相同的程序,除了在步驟b中使用NH4
OH替代二甲胺。粗化合物藉由矽膠層析法(首先為10-100%乙酸乙酯/己烷,且接著為0-15% MeOH/EtOAc)純化,得到(2R
,3S
)-2-[4-[(2-胺基乙醯基)-環戊基-胺基]苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺。MS:C35
H38
F4
N4
O3
[M + H]+
之(ES)m/z
計算值為638.3,實驗值為638.8。實例 3 : 2-[[[N
- 環戊基 -4-[(2R
,3S
)-1-(2- 氟基 -6- 甲基 - 苯甲醯基 )-3-[[4- 甲基 -3-( 三氟甲基 ) 苯基 ] 胺甲醯基 ]-2- 哌啶基 ] 苯胺基 ]- 羥基 - 磷醯基 ] 胺基 ]-3-(1H
- 咪唑 -4- 基 ) 丙酸之合成 步驟a:在0℃下,向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(1.0 g,1.78 mmol)於三乙胺(3.0 mL)中之攪拌溶液中添加POCl3
(2.61 g,17.8 mmol)。在0℃下攪拌反應混合物2 h,且隨後使其升溫至室溫並攪拌36 h。反應完成後,在0℃下用冰淬滅反應,攪拌1 h並過濾。粗化合物藉由矽膠層析法(5-60%乙酸乙酯/己烷)純化,得到所要產物:(2R
,3S
)-2-[4-[環戊基(二氯磷醯基)-胺基]苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]-哌啶-3-甲醯胺。MS:C33
H34
Cl2
F4
N3
O3
P[M + H]+
之(ES)m/z
計算值為698.1,實驗值為698.6。 步驟b:向(2R
,3S
)-2-[4-[環戊基(二氯磷醯基)胺基]苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(250 mg,0.36 mmol)於無水THF (4 mL)中之攪拌溶液中添加(2S
)-2-胺基-3-(1H
-咪唑-4-基)丙酸甲酯(216 mg,0.89 mmol)及N,N-
二異丙基乙胺(231 mg,1.79 mmol)。在室溫下攪拌混合物隔夜。反應完成後,添加水(2 mL)並攪拌2 h。隨後,反應混合物用EtOAc萃取,用鹽水洗滌,經Na2
SO4
乾燥且在真空中濃縮。粗產物藉由矽膠層析法(0-100% EtOAc/己烷)純化,得到游離酸,該游離酸隨後用1N NaOH (1當量)處理且經凍乾,獲得2-[[[N
-環戊基-4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯胺基]-羥基-磷醯基]胺基]-3-(1H
-咪唑-4-基)丙酸。MS:C39
H43
F4
N6
O6
P[M + H]+
之(ES)m/z
計算值為799.3,實驗值為799.7。實例 4 : N - 環戊基 -N
-[4-[(2R
,3S
)-1-(2- 氟基 -6- 甲基 - 苯甲醯基 )-3-[[4- 甲基 -3( 三氟甲基 ) 苯基 ] 胺甲醯基 ]-2- 哌啶基 ] 苯基 ]-(2- 甲基丙醯基氧基 ) 磷醯胺酸之合成 向(2R
,3S
)-2-[4-[環戊基(二氯磷醯基)胺基]苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(200 mg,0.28 mmol,參見實例3)於乙酸乙酯(4 mL)中之攪拌溶液中添加異丁酸鈉鹽(85 mg,0.72 mmol)。在室溫下攪拌反應混合物隔夜。反應完成後,添加飽和NH4
Cl水溶液,用EtOAc萃取,在真空中濃縮。粗產物藉由矽膠層析法(0-20% MeOH/CH2
Cl2
)純化,得到N
-環戊基-N
-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]-(2-甲基丙醯基氧基)磷醯胺酸。MS:C37
H42
F4
N3
O6
P[M + H]+
之(ES)m/z
計算值為732.3,實驗值為732.3。實例 5 : (2R
,3S
)-2-[4-[[2-[(2- 胺基乙醯基 ) 胺基 ] 乙醯基 ]- 環戊基 - 胺基 ] 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 )-N
-[4- 甲基 -3-( 三氟甲基 ) 苯基 ] 哌啶 -3- 甲醯胺之合成 將(2R
,3S
)-2-[4-[(2-胺基乙醯基)-環戊基-胺基]苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(200 mg,0.31 mmol)、2-(第三丁氧基羰基胺基)乙酸(82 mg,0.46 mmol)、EDCI (118 mg,0.62 mmol)、HOBT (71 mg,0.46 mmol)及DIPEA (99 mg,0.77 mmol)添加至具有DMF (2 mL)之小瓶中。在室溫下攪拌反應混合物24 h。反應完成後,反應混合物用EtOAc稀釋,用飽和NaHCO3
水溶液及水洗滌,經Na2
SO4
乾燥且在真空中濃縮。粗產物藉由矽膠層析法(10-100% EtOAc/己烷)純化。隨後將所要物質溶解於CH2
Cl2
(3 mL)中,且在rt下用含2N HCl之二噁烷(2 mL)處理2 h。反應完成後,移除溶劑,且殘餘物用CH2
Cl2
稀釋並用飽和NaHCO3
水溶液及水洗滌,經Na2
SO4
乾燥且在真空中濃縮。粗產物藉由矽膠層析法(0-20% MeOH/CH2
Cl2
)純化,得到(2R
,3S
)-2-[4-[[2-[(2-胺基乙醯基)胺基]乙醯基]-環戊基-胺基]苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺。MS:C37
H41
F4
N5
O4
[M + H]+
之(ES)m/z
計算值為696.3,實驗值為696.7。實例 6 : (2R
,3S
)-2-[4-[ 環戊基 -[2-[[(2S
)-2,5- 二 胺基 戊醯基 ] 胺基 ] 乙醯基 ] 胺基 ] 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 )-N
-[4- 甲基 -3-( 三氟甲基 ) 苯基 ] 哌啶 -3- 甲醯胺二鹽酸鹽之合成 將(2R
,3S
)-2-[4-[(2-胺基乙醯基)-環戊基-胺基]苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(250 mg,0.39 mmol)、(2S
)-2,5-雙(第三丁氧基羰基胺基)戊酸(309 mg,0.59 mmol)、EDCI (150 mg,0.78 mmol)、HOBT (90 mg,0.59 mmol)及DIPEA (151 mg,1.17 mmol)添加至具有DMF (3.0 mL)之小瓶中。在室溫下攪拌反應物24 h。反應完成後,用EtOAc稀釋,用水洗滌,經Na2
SO4
乾燥且在真空中濃縮。粗產物藉由矽膠層析法(首先為10-100% EtOAc/己烷,隨後為0-20% MeOH/CH2
Cl2
)純化。隨後,將產物溶解於CH2
Cl2
(3 mL)中,且在rt下用含2N HCl之二噁烷(2 mL)處理2 h。反應完成後,移除溶劑並用CH3
CN濕磨殘餘物,得到(2R
,3S
)-2-[4-[環戊基-[2-[[(2S
)-2,5-二胺基戊醯基]胺基]乙醯基]胺基]苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺二鹽酸鹽。MS:C40
H48
F4
N6
O4
[M + H]+
之(ES)m/z
計算值為752.4,實驗值為752.4。實例 7 : (2S
)-2- 胺基 -3- 甲基 - 丁酸 [ 環戊基 -[4-[(2R
,3S
)-1-(2- 氟基 -6- 甲基 - 苯甲醯基 )-3-[[4- 甲基 -3-( 三氟甲基 ) 苯基 ] 胺甲醯基 ]-2- 哌啶基 ] 苯基 ] 胺甲醯基 ] 氧基甲酯之合成 步驟a:在0℃下,向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(3.0 g,5.15 mmol)於無水二氯甲烷(25 mL)中之攪拌溶液中添加DIPEA (997 mg,7072 mmol)及氯甲酸氯甲酯(791 mg,6.02 mmol)。攪拌混合物2 h。反應完成後,反應物用水淬滅,用CH2
Cl2
萃取,並得到粗產物:N
-環戊基-N
-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]胺基甲酸氯甲酯(3.5 g,產率:100%)。MS:C35
H36
ClF4
N3
O4
[M + H]+
之(ES)m/z
計算值為674.2,實驗值為674.5。 步驟b:在室溫下,向N
-環戊基-N
-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]胺基甲酸氯甲酯(450 mg,0.67 mmol)於無水THF (5.0 mL)中之攪拌溶液中添加由混合及凍乾(2S
)-2-(苯甲氧基羰基胺基)-3-甲基-丁酸(251 mg,1 mmol)與氫氧化四丁銨(260 mg,1 mmol)所獲得之加合物。在室溫下攪拌反應物48 h。反應完成後,混合物用水淬滅,用EtOAc萃取且藉由矽膠層析法(10-50%乙酸乙酯/己烷)純化,得到所需中間物。隨後,使用鈀/碳作為催化劑使該中間物在甲醇中氫化,得到所需產物:(2S
)-2-胺基-3-甲基-丁酸[環戊基-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]胺甲醯基]氧基甲酯。MS:C40
H46
F4
N4
O6
[M + H]+
之(ES)m/z
計算值為755.3,實驗值為755.5。實例 8 : 合成 N - 環戊基 -N
-[4-[(2R
,3S
)-1-(2- 氟基 -6- 甲基 - 苯甲醯基 )-3-[[4- 甲基 -3-( 三氟甲基 ) 苯基 ] 胺甲醯基 ]-2- 哌啶基 ] 苯基 ] 胺基甲酸 (4- 膦醯氧基苯基 ) 甲酯 步驟a:在rt下,向[4-(羥甲基)苯基]磷酸二乙酯(0.3 g,1.14 mmol)於無水二氯甲烷(4 mL)中之攪拌溶液中添加三光氣(0.67 g,2.29 mmol)並攪拌4 h。隨後,移除溶劑且在真空下乾燥30 min。所得殘餘物直接用於下一步驟中。 步驟b:向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(0.66 g,1.13 mmol)及N,N
-二異丙基乙胺(598 mg,4.63 mmol)於二氯甲烷(5 mL)中之溶液中添加上述殘餘物。在室溫下攪拌反應混合物隔夜。反應完成後,反應物藉由水洗處理,且用CH2
Cl2
萃取。粗產物藉由矽膠層析法(20-100%乙酸乙酯/己烷)純化,得到所需中間物。隨後,將此中間物(80 mg)溶解於CH2
Cl2
(1 mL)中,且在室溫下用溴三甲基矽烷(84 mg,0.55 mmol)處理隔夜。反應完成後,反應混合物經濃縮至乾燥且藉由製備型HPLC (含有0.1% TFA之乙腈-水)純化,得到N
-環戊基-N
-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]胺基甲酸(4-膦醯氧基苯基)甲酯。MS:C41
H42
F4
N3
O8
P[M + H]+
之(ES)m/z
計算值為812.3,實驗值為812.4。實例 9 : N - 環戊基 -N
-[4-[(2R
,3S
)-1-(2- 氟基 -6- 甲基 - 苯甲醯基 )-3-[[4- 甲基 -3-( 三氟甲基 ) 苯基 ] 胺甲醯基 ]-2- 哌啶基 ] 苯基 ] 胺基甲酸膦醯氧基甲酯之二鈉鹽之合成 步驟a:在0℃下,向氯甲酸二苯甲氧基磷醯基氧基甲酯(526 mg,(約60%純度,1.05 g,如WO 2014/193696中所描述加以製備),1.42 mmol)於無水二氯甲烷(10 mL)中之攪拌溶液中添加DIPEA (1.3 mL,7.1 mmol)。隨後,在0℃下,添加(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(826 mg,1.42 mmol)於無水二氯甲烷(5 mL)中之溶液。攪拌混合物2 h。反應完成後,反應物用水淬滅,用CH2
Cl2
萃取,經Mg2
SO4
乾燥且在真空中濃縮。粗產物藉由矽膠層析法(20-100% EtOAc/己烷)純化,得到所需產物:N
-環戊基-N
-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]胺基甲酸二苯甲氧基磷醯基氧基甲酯。MS:C49
H50
F4
N3
O8
P[M + H]+
之(ES)m/z
計算值為916.6,實驗值為916.6。 步驟b:向N
-環戊基-N
-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]胺基甲酸二苯甲氧基磷醯基氧基甲酯(690 mg,0.75 mmol)於乙酸乙酯(15 mL)中之溶液中添加鈀/碳(2 g,10重量%),在60 psi下氫化20 min,經由矽藻土過濾,用1:1之EtOAc/MeOH (15 mL)沖洗,濃縮至乾燥。將殘餘物溶解於MeOH中,且用1M NaOMe (1.57 mL,1.57 mmol)處理。將混合物在真空中濃縮至乾燥並添加溶劑乙醚,隨後過濾且用溶劑乙醚沖洗,得到N
-環戊基-N
-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]胺基甲酸膦醯氧基甲酯之二鈉鹽,MS:C35
H38
F4
N3
O8
P[M + H]+
之(ES)m/z
計算值為736.6,實驗值為736.6。實例 10 : (E
)-4-[[ 環戊基 -[4-[(2R
,3S
)-1-(2- 氟基 -6- 甲基 - 苯甲醯基 )-3-[[4- 甲基 -3-( 三氟甲基 ) 苯基 ] 胺甲醯基 ]-2- 哌啶基 ] 苯基 ] 胺甲醯基 ] 氧基甲氧基 ]-4- 側氧基 - 丁 -2- 烯酸之鈉鹽之合成 步驟a:在0℃下,向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(1 g,1.72 mmol)於無水THF (10 mL)中之攪拌溶液中添加氯甲酸氯甲酯(155 µL,1.72 mmol)及N,N
-二異丙基乙胺(392 µL, 2.58 mmol),持續1 h。反應完成後,移除溶劑且獲得N
-環戊基-N
-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]胺基甲酸氯甲酯。 步驟b:在rt下,向N
-環戊基-N
-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]胺基甲酸氯甲酯(200 mg,0.297 mmol)及反丁烯二酸四丁基銨鹽(106 mg,0.297 mmol)於THF (5 mL)中之溶液中添加含碘化四丁基銨(22 mg,0.06 mmol)之DMF。攪拌混合物隔夜,隨後用EtOAc稀釋,用經0.1 M HCl洗滌,經Na2
SO4
乾燥且在真空中濃縮。粗產物藉由矽膠層析法5-10% MeOH/CH2
Cl2
純化。藉由用CH3
CN (0.6 mL)/H2
O (0.4 mL)稀釋並添加0.1 M NaOH (213 µL,1當量)來將所採集產物轉化成鈉鹽。凍乾並獲得(E
)-4-[[環戊基-[4-[(2R
,3S
)-1-(2-氟基-6-甲基-苯甲醯基)-3-[[4-甲基-3-(三氟甲基)苯基]胺甲醯基]-2-哌啶基]苯基]胺甲醯基]氧基甲氧基]-4-側氧基-丁-2-烯酸之鈉鹽。MS:C39
H38
F4
N3
O8
[M + H]+
之(ES)m/z
計算值為754.2,實驗值為754.7。實例 11 : 磷酸二氫 [N
-[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ]-4- 甲基 -3-( 三氟甲基 ) 苯胺基 ] 甲酯之二鈉鹽之合成 向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(1.99 g,3.42 mmol)及多聚甲醛(308 mg,10.26 mmol)於二噁烷(10 mL)中之懸浮液中添加氯三甲基矽烷(20 mL,157.58 mmol)且使其升溫至70℃。攪拌反應物9 h,且隨後在真空中濃縮。將殘餘物溶解於THF (10 mL)中,且添加磷酸二氫四丁基銨(3.7 g,10.9 mmol)。在40℃下攪拌混合物1 h,隨後用氫氧化銨(5 mL)、水(20 mL)及CH2
Cl2
(30 mL)處理。在真空中濃縮有機層,且首先藉由矽膠層析法(3-60% (4:1體積之MeOH:NH4
OH)/CH2
Cl2
)進行純化。隨後,藉由製備型HPLC (含0.1% NH4
HCO3
/ACN之乙腈-水)純化該有機層。採集所需溶離份並在真空中濃縮。隨後,用2 mL H2
O、1 mL CH3
CN及1N NaOH (137 µL,2當量)處理殘餘物,凍乾且獲得磷酸二氫[N
-[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]-4-甲基-3-(三氟甲基)苯胺基]甲酯之二鈉鹽,MS:C34
H38
F4
N3
O6
P[M + H]+
之(ES)m/z
計算值為692.2,實驗值為692.6。實例 12 : [N
-[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ]-4- 甲基 -3-( 三氟甲基 ) 苯胺基 ] 膦酸之合成 在-78℃下,向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-甲基-3-(三氟甲基)苯基]哌啶-3-甲醯胺(291 mg,0.50 mmol)於THF (3 mL)中之攪拌溶液中添加LHMDS (72 µL,0.55 mmol)。攪拌混合物5 min。添加1-[氯(乙氧基)磷醯基]氧基乙烷(72 µL,0.50 mmol)且使其緩慢升溫至rt。在反應完成時,反應物用EtOAc稀釋,用飽和NaHCO3
溶液洗滌,且用EtOAc萃取。粗產物藉由矽膠層析法(0-100% EtOAc/己烷)純化,得到60 mg所需中間物。在0℃下,將此中間物溶解於CH2
Cl2
(1 mL)中且添加TMSBr (0.2 mL)。使混合物升溫達至rt並攪拌2 h。隨後,反應物在真空中濃縮且藉由製備型HPLC (含0.1% TFA之乙腈-水)純化,得到[N
-[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]-4-甲基-3-(三氟甲基)苯胺基]膦酸。MS:C33
H36
F4
N3
O5
P[M + H]+
之(ES)m/z
計算值為662.3,實驗值為662.3。實例 13 : 2-[(2- 胺基乙醯基 ) 胺基 ] 乙酸 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲酯之合成 將(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(220 mg,0.37 mmol)、2-[[2-(第三丁氧基羰基胺基)乙醯基]胺基]乙酸(213 mg,0.92 mmol)、HATU (210 mg,0.55 mmol)及DIPEA (95 mg,0.74 mmol)添加至具有DMF (2 mL)之小瓶中。在55℃下攪拌反應物24 h。反應完成後,反應混合物用EtOAc稀釋,用飽和NaHCO3
水溶液及水洗滌,經Na2
SO4
乾燥且在真空中濃縮。隨後,將殘餘物溶解於CH2
Cl2
(3 mL)中,且在rt下用含2N HCl之二噁烷(2 mL)處理2 h。反應完成後,移除溶劑,且殘餘物用CH2
Cl2
稀釋並用飽和NaHCO3
水溶液及水洗滌,經Na2
SO4
乾燥且在真空中濃縮。粗產物藉由矽膠層析法(0-20% MeOH/CH2
Cl2
)純化,得到2-[(2-胺基乙醯基)胺基]乙酸[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲酯。MS:C37
H41
F4
N5
O5
[M + H]+
之(ES)m/z
計算值為712.3,實驗值為712.7。實例 14 : 2-[[(2S
)-2- 胺基 -3- 甲基 - 丁醯基 ] 胺基 ] 乙酸 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲酯之合成 將(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(200 mg,0.33 mmol)、2-[[(2S
)-2-(第三丁氧基羰基胺基)-3-甲基-丁醯基]胺基]乙酸(138 mg,0.50 mmol)、HATU (190 mg,0.50 mmol)及DIPEA (108 mg,0.84 mmol)添加至具有DMF (2.0 mL)之小瓶中。遵循與實例1相同之程序,得到產物:2-[[(2S
)-2-胺基-3-甲基-丁醯基]胺基]乙酸[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲酯。MS:C40
H47
F4
N5
O5
[M + H]+
之(ES)m/z
計算值為754.3,實驗值為754.8。實例 15 : (2S
)-2-[(2- 胺基乙醯基 ) 胺基 ]-3- 甲基 - 丁酸 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲酯之合成 將(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(250 mg,0.42 mmol)、(2S
)-2-[[2-(第三丁氧基羰基胺基)乙醯基]胺基]-3-甲基-丁酸(172 mg,0.62 mmol)、EDCI (160 mg,0.83 mmol)、HOBT (96 mg,0.62 mmol)及DIPEA (108 mg,0.83 mmol)添加至具有DMF (2.5 mL)之小瓶中。在室溫下攪拌反應物24 h。反應完成後,用EtOAc稀釋,用水洗滌,經Na2
SO4
乾燥且在真空中濃縮。粗產物藉由矽膠層析法(首先為10-100% EtOAc/己烷,隨後為0-20% MeOH/CH2
Cl2
)純化。隨後,將產物溶解於CH2
Cl2
(3 mL)中,且在rt下用含2N HCl之二噁烷(2 mL)處理2 h。反應完成後,反應物用CH2
Cl2
稀釋並用飽和NaHCO3
及水洗滌,經Na2
SO4
乾燥且在真空中濃縮。粗產物藉由矽膠層析法(0-20% MeOH/CH2
Cl2
)純化,得到產物:(2S
)-2-[(2-胺基乙醯基)胺基]-3-甲基-丁酸[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲酯。MS:C40
H47
F4
N5
O5
[M + H]+
之(ES)m/z
計算值為754.3,實驗值為754.8。實例 16 : (2S
)-2-[[(2S
)-2- 胺基 -3- 甲基 - 丁醯基 ] 胺基 ]-3- 甲基 - 丁酸 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲酯之合成 將(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(250 mg,0.42 mmol)、(2S
)-2-[[(2S
)-2-(第三丁氧基羰基胺基)-3-甲基-丁醯基]胺基]-3-甲基-丁酸(196 mg,0.62 mmol)、EDCI (160 mg,0.83 mmol)、HOBT (96 mg,0.62 mmol)及DIPEA (108 mg,0.83 mmol)添加至具有DMF (2.0 mL)之小瓶中。遵循與實例3相同之程序,得到產物:(2S
)-2-[[(2S
)-2-胺基-3-甲基-丁醯基]胺基]-3-甲基-丁酸[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲酯。MS:C43
H53
F4
N5
O5
[M + H]+
之(ES)m/z
計算值為796.4,實驗值為796.8。實例 17 : (2R
)-2- 胺基 -3- 甲基 - 丁酸 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲酯之合成 將(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(250 mg,0.42 mmol)、(2S
)-2-(第三丁氧基羰基胺基)-3-甲基-丁酸(180 mg,0.83 mmol)、EDCI (160 mg,0.83 mmol)、HOBT (96 mg,0.62 mmol)及DIPEA (108 mg,0.83 mmol)添加至具有DMF (4 mL)之小瓶中。遵循與實例3相同之程序,得到產物:(2S
)-2-胺基-3-甲基-丁酸[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲酯。MS:C38
H44
F4
N4
O4
[M + H]+
之(ES)m/z
計算值為697.4,實驗值為697.7。實例 18 : (2S
)-2- 胺基丙酸 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲酯之合成 將(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(250 mg,0.42 mmol)、(2S
)-2-(第三丁氧基羰基胺基)丙酸(118 mg,0.62 mmol)、EDCI (119 mg,0.83 mmol)、HOBT (96 mg,0.62 mmol)及DIPEA (134 mg,1.04 mmol)添加至具有DMF (4.0 mL)之小瓶中。遵循與實例3相同之程序,得到產物:(2S
)-2-胺基丙酸[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲酯。MS:C36
H40
F4
N4
O4
[M + H]+
之(ES)m/z
計算值為669.3,實驗值為669.7。實例 19 : 2-( 二甲胺基 ) 乙酸 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲酯之合成 向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(70 mg,0.12 mmol)及2-(二甲胺基)乙酸鹽酸鹽(49 mg,0.35 mmol)於DMF (2.5 mL)中之攪拌溶液中添加HATU (135 mg,0.36 mmol)及三乙胺(82 µL,0.59 mmol)。使混合物升溫至70℃並攪拌2 h。隨後,使其冷卻至rt,用EtOAc稀釋,用飽和NaHCO3
水溶液及水洗滌,且在真空中濃縮。粗產物藉由矽膠層析法(0-100% EtOAc/己烷)純化,得到2-(二甲胺基)乙酸[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲酯,MS:C37
H42
F4
N4
O4
[M + H]+
之(ES)m/z
計算值為683.3,實驗值為683.3。實例 20 : 2- 胺基乙酸 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲酯之合成 向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(100 mg,0.17 mmol)及2-(第三丁氧基羰基胺基)乙酸(88 mg,0.50 mmol)於DMF (2.5 mL)中之攪拌溶液中添加HATU (190 mg,0.50 mmol)及三乙胺(129 µL,0.92 mmol)。使混合物升溫至60℃並攪拌1小時。隨後,使其冷卻至rt,用EtOAc稀釋,用飽和NaHCO3
水溶液及水洗滌,且在真空中濃縮。粗產物藉由矽膠層析法(0-90% EtOAc/己烷)純化,得到110 mg所需中間物。將此中間物溶解於CH2
Cl2
(2 mL)中,且在rt下用含4M HCl之二噁烷(2 mL)處理45 min。隨後,使反應物冷卻至rt,用EtOAc稀釋,用飽和NaHCO3
溶液及水洗滌,且用EtOAc萃取。粗產物藉由矽膠層析法(0-20% MeOH/EtOAc)純化,得到2-胺基乙酸[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲酯,MS:C35
H38
F4
N4
O4
[M + H]+
之(ES)m/z
計算值為655.3,實驗值為655.3。實例 21 : 磷酸二氫 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲酯之合成 向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(100 mg,0.17 mmol)及磷酸(100 mg,1 mmol)之攪拌混合物中添加2,2,2-三氯乙腈(720 mg,5 mmol)及三乙胺(280 µL,2 mmol)。在rt下攪拌混合物2 h。隨後,混合物用1% TFA/H2
O淬滅且用 i
PrOH/CHCl3
(1:3)萃取。粗產物藉由梯度為0-60% (10% HOAc/MeOH)/CH2
Cl2
之矽膠層析法純化,得到磷酸二氫[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲酯,MS:C33
H36
F4
N3
O6
P[M + H]+
之(ES)m/z
計算值為678.3,實驗值為678.3。實例 22 : 磷酸二氫 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲氧基甲酯之二鈉鹽之合成 向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(598 mg,1.0 mmol)及多聚甲醛(120 mg,4.0 mmol)於二噁烷(8 mL)中之攪拌懸浮液中添加氯三甲基矽烷(8 mL)及磷酸(1.0 g,10.0 mmol)。攪拌反應物9 h,且隨後在真空中濃縮。在rt下,將殘餘物溶解於CH3
CN (5 mL)中,且添加至85% H3
PO4
於水(1.2 mL)、DIPEA (5.2 mL)於CH3
CN (15 mL)中之溶液中。在rt下攪拌30 min之後,在真空中濃縮反應混合物。向此粗殘餘物中添加水(30 mL),且在rt下攪拌30 min。過濾所得固體,用水(10 mL)洗滌且在高真空下乾燥。隨後,用1:1之EtOAc-Et2
O (20 mL)洗滌固體,以移除非極性雜質。所得粗產物藉由製備型HPLC (含0.1% Et3
N之乙腈-水)純化,得到為二三甲胺鹽之產物,該產物用0.1 M NaOH (11.7 mL)及CH3
CN (12 mL)處理且凍乾,得到磷酸二氫[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲氧基甲酯之二鈉鹽,MS:C34
H38
F4
N3
O7
P[M + H]+
之(ES)m/z
計算值為708.2,實驗值為708.2。實例 23 : 3-[(4- 甲基哌嗪 -1- 基 ) 甲基 ] 苯甲酸 [4-[[(2R
,3S
)-2-[4-( 環戊基胺基 ) 苯基 ]-1-(2- 氟基 -6- 甲基 - 苯甲醯基 ) 哌啶 -3- 羰基 ] 胺基 ]-2-( 三氟甲基 ) 苯基 ] 甲酯之合成 向(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)-N
-[4-(羥甲基)-3-(三氟甲基)苯基]哌啶-3-甲醯胺(511 mg,0.85 mmol)及3-[(4-甲基哌嗪-1-基)甲基]苯甲酸(200 mg,0.85 mmol)於DMF (5 mL)中之攪拌溶液中添加HATU (485 mg,1.27 mmol)及N,N
-二異丙基乙胺(443 μL,2.55 mmol)。使混合物升溫達至70℃並攪拌2 h。隨後使反應物冷卻至rt,用EtOAc稀釋,用飽和NaHCO3
溶液及水洗滌,且在真空下濃縮。粗產物藉由矽膠層析法(0-20% MeOH/CH2
Cl2
)純化,得到3-[(4-甲基哌嗪-1-基)甲基]苯甲酸[4-[[(2R
,3S
)-2-[4-(環戊基胺基)苯基]-1-(2-氟基-6-甲基-苯甲醯基)哌啶-3-羰基]胺基]-2-(三氟甲基)苯基]甲酯。MS:C46
H51
F4
N5
O4
[M + H]+
之(ES)m/z
計算值為814.3,實驗值為814.8。實例 24 : 化合物之溶解度
藉由在室溫下將指定任意量之化合物懸浮於1 mL之Milli-Q水中且在充分震盪小瓶後藉由肉眼檢查來獲得以下化合物之溶解度。具有肉眼不可見之顆粒的實驗物被認為是清澈溶液。值得注意的是,所報告之溶解度資訊並不係化合物於水中之最大溶解度。
使用以下方案來測定下表中之第一化合物之溶解度。將含化合物之飽和溶液的pH 7緩衝液在室溫(25℃)下靜置隔夜,之後將其離心。取出上清液並定量。溶解度:0.053 µg/mL。 使用以下方案來測定下表中之第二化合物之溶解度。藉由將1 mL D.I.水添加至0.8 mg化合物粉末中來新鮮製備化合物之飽和溶液。在室溫下振盪3小時之後,將樣本在14000 rpm下離心15分鐘,進行兩次。謹慎地取出上清液並藉由LC-MS定量。溶解度:1.2 ±0.2 µg/mL (四次重複之平均值)。 實例 25 : 大鼠中之靜脈內注射
自Charles River Laboratories (Hollister, CA)購得重量在0.22 kg至0.25 kg之間的雄性大鼠,並在使用前使其適應新環境。所有化合物均在溶液調配物中製備,且經由靜脈內給藥投與給動物。實例11之化合物在無菌水中製備,且各動物接受1 mL/kg。實例22之化合物在0.9%標準生理鹽水中製備,且各動物接受1 mL/kg。在給藥前2 min、5 min、10 min、15 min及30 min,在靜脈內給藥後1小時、2小時、4小時、6小時及8小時,經由頸靜脈或心臟穿刺(僅針對末梢點)取樣血液(0.2 mL)。將血液樣本採集至含有鈉EDTA作為抗凝血劑之冷凍聚丙烯試管中,且經由在10,000 rpm及4℃下離心(Eppendorf Centrifuge 5417R) 6分鐘來採集血漿,並在‑20℃下存放直至分析。 在線性振盪器上用含有內標物之150 µL乙腈萃取血漿樣品(50 µL)持續10 min,並接著在3700 g、4℃下離心10 min (Allegra X-15R centrifuge, Beckman Coulter, Inc., Fullerton, CA)。將一百µL之所得上清液轉移至新的培養盤中且與100 µL之含0.1%甲酸之水混合,以用於LC-MS/MS分析。如圖1及圖2所示出,在雄性大鼠中靜脈內注射兩種化合物之後,釋放出良好量之活性藥物。
圖 1
為展示活性化合物1.543 (來自WO 2011/163640)自實例22之化合物之釋放的曲線圖。圖 2
為展示活性化合物1.172 (來自WO 2010/075257)自實例11之化合物之釋放的曲線圖。
Claims (33)
- 一種式(I)化合物
- 如請求項1之化合物或其醫藥學上可接受之鹽,其中R1選自由以下各者組成之群:O-(CO)-C1-6伸烷基-NReRf、O-(CO)-C1-6伸烷基-NRd(CO)-C1-6伸烷基-NReRf、O-P(O)ORaORb、O-CH2-O-P(O)ORaORb及O-(CO)-C6-10伸芳基-C1-3伸烷基-C4-7雜環基,其中該C4-7雜環基選自由以下各者組成之群:哌啶基、哌嗪基、吡咯啶基、嗎啉基及氮雜環丁基,且其中該哌啶基、該哌嗪基、該吡咯啶基、該嗎啉基及該氮雜環丁基視情況經1至6個Rc基團取代。
- 如請求項1之化合物或其醫藥學上可接受之鹽,其中R3選自由-CH2-O-P(O)ORaORb及-P(O)ORaORb組成之群。
- 如請求項1之化合物或其醫藥學上可接受之鹽,其中R2選自由以下各者組成之群:-(CO)-C1-6伸烷基-NRkRl、-(CO)-O-C1-6伸烷基-O-P(O)ORaORb、-P(O)ORaO(CO)-C1-6烷基、-P(O)ORaNRgRh、-(CO)-O-C1-6伸烷基-O-(CO)-C2-6伸烯基-CO2H、-(CO)-C1-6伸烷基-NRd(CO)-C1-6伸烷基-NRkRl,其中該C1-6伸烷基-NRkRl可視情況經NReRf、-(CO)-O-C1-6伸烷基-O-(CO)-C1-6伸烷基-NRkRl及-(CO)-O-C1-6伸烷基-C6-10芳基-O-P(O)ORaORb取代,其中該C6-10芳基視情況經可相同或不同的1至5個Rx取代。
- 如請求項1、2、7、12及14中任一項之化合物或其醫藥學上可接受之鹽,其呈醫藥學上可接受之鹽的形式。
- 如請求項18之化合物或其醫藥學上可接受之鹽,其中該醫藥學上可接受之鹽選自由以下各者組成之群:銨、鈣、鎂、鉀、鈉、鋅、精胺酸、 甜菜鹼、咖啡鹼、膽鹼、N,N'-二苯甲基乙二胺、二乙胺、2-二乙胺基乙醇、2-二甲胺基乙醇、乙醇胺、乙二胺、N-乙基嗎啉、N-乙基哌啶、還原葡糖胺、葡糖胺、組胺酸、海卓胺、異丙胺、離胺酸、甲基還原葡糖胺、嗎啉、哌嗪、哌啶、普魯卡因(procaine)、嘌呤、可可豆鹼、三乙胺、三甲胺、三丙胺、緩血酸胺、鹽酸、碳酸、一氫碳酸、磷酸、一氫磷酸、二氫磷酸、乙酸、丙酸、異丁酸、丙二酸、苯甲酸、丁二酸、辛二酸、反丁烯二酸、杏仁酸、鄰苯二甲酸、苯磺酸、對甲苯磺酸、檸檬酸、酒石酸、甲磺酸、精胺酸、葡糖醛酸及半乳糖醛酸。
- 一種醫藥組合物,其包含如請求項1至19中任一項之化合物或其醫藥學上可接受之鹽及醫藥學上可接受之賦形劑。
- 如請求項20之醫藥組合物,其經調配用於靜脈內、經皮或皮下投與。
- 如請求項20或21之醫藥組合物,其進一步包含一或多種其他治療劑。
- 如請求項22之醫藥組合物,其中該一或多種其他治療劑選自由以下各者組成之群:皮質類固醇、類固醇、免疫抑制劑、免疫球蛋白G促效劑、二肽基肽酶IV抑制劑、淋巴細胞功能抗原-3受體拮抗劑、介白素-2配位體、介白素-1 β配位體抑制劑、IL-2受體α次單位抑制劑、HGF基因刺激劑、IL-6拮抗劑、IL-5拮抗劑、α 1抗胰蛋白酶刺激劑、類大麻鹼受體 拮抗劑、組蛋白脫乙醯基酶抑制劑、AKT蛋白激酶抑制劑、CD20抑制劑、Abl酪胺酸激酶抑制劑、JAK酪胺酸激酶抑制劑、TNF α配位體抑制劑、血紅蛋白調節劑、TNF拮抗劑、蛋白酶體抑制劑、CD3調節劑、Hsp 70家族抑制劑、免疫球蛋白促效劑、CD30拮抗劑、微管蛋白拮抗劑、神經鞘胺醇-1-磷酸酯受體-1促效劑、結締組織生長因子配位體抑制劑、卡斯蛋白酶抑制劑、促腎上腺皮質激素配位體、Btk酪胺酸激酶抑制劑、補體C1s子組分抑制劑、紅血球生成素受體促效劑、B-淋巴細胞刺激子配位體抑制劑、週期蛋白依賴型激酶-2抑制劑、P-選擇素醣蛋白配位體-1刺激劑、mTOR抑制劑、延長因子2抑制劑、細胞黏附分子抑制劑、XIII因子促效劑、鈣調神經磷酸酶抑制劑、免疫球蛋白G1促效劑、肌核苷單磷酸去氫酶抑制劑、補體C1s子組分抑制劑、胸苷激酶調節劑、細胞毒性T-淋巴細胞蛋白-4調節劑、血管緊張素II受體拮抗劑、血管緊張素II受體調節劑、TNF超家族受體12A拮抗劑、CD52拮抗劑、腺苷脫胺酶抑制劑、T細胞分化抗原CD6抑制劑、FGF-7配位體、二氫乳清酸去氫酶抑制劑、CCR5趨化介素拮抗劑、CCR2趨化介素拮抗劑、Syk酪胺酸激酶抑制劑、I型干擾素受體拮抗劑、α干擾素配位體抑制劑、巨噬細胞遷移抑制因子抑制劑、整合素α-V/β-6拮抗劑、半胱胺酸蛋白酶刺激劑、p38 MAP激酶抑制劑、TP53基因抑制劑、志賀樣毒素I(Shiga like toxin I)抑制劑、海藻糖基轉移酶6刺激劑、介白素22配位體、CXCR1趨化介素拮抗劑、CXCR4趨化介素拮抗劑、IRS1基因抑制劑、蛋白激酶C刺激劑、蛋白激酶C α抑制劑、CD74拮抗劑、免疫球蛋白γ Fc受體IIB拮抗劑、T細胞抗原CD7抑制劑、CD95拮抗劑、N乙醯甘露糖胺激酶刺激劑、心營養素-1配位體、白細胞彈性蛋白酶抑制劑、CD40配位體受體拮抗劑、CD40配位體調 節劑、IL-17拮抗劑、TLR-2拮抗劑、甘露聚糖結合凝集素絲胺酸蛋白酶-2(MASP-2)抑制劑、B因子抑制劑、D因子抑制劑及T細胞受體拮抗劑,及其組合。
- 如請求項22之醫藥組合物,其中該一或多種其他治療劑選自由以下各者組成之群:歐比托珠單抗(obinutuzumab)、利妥昔單抗(rituximab)、奧克珠單抗(ocrelizumab)、環磷醯胺、潑尼松(prednisone)、氫化皮質酮、氫化皮質酮乙酸酯、皮質酮乙酸酯、替可的松特戊酸酯(tixocortol pivalate)、潑尼龍(prednisolone)、甲基潑尼龍、曲安奈德(triamcinolone acetonide)、曲安西龍醇(triamcinolone alcohol)、莫米松(mometasone)、安西奈德(amcinonide)、布地奈德(budesonide)、地奈德(desonide)、氟西奈德(fluocinonide)、丙酮化氟新龍(fluocinolone acetonide)、哈西奈德(halcinonide)、倍他米松(betamethasone)、倍他米松磷酸鈉、地塞米松(dexamethasone)、地塞米松磷酸鈉、氟可龍(fluocortolone)、氫化皮質酮-17-戊酸酯、鹵米松(halometasone)、阿氯米松二丙酸酯(alclometasone dipropionate)、倍氯米松(beclomethasone)、倍他米松戊酸酯、倍他米松二丙酸酯、潑尼卡酯(prednicarbate)、氯倍他松-17-丁酸酯(clobetasone-17-butyrate)、氯倍他索-17-丙酸酯(clobetasol-17-propionate)、氟可龍己酸酯、氟可龍特戊酸酯、氟潑尼定乙酸酯(fluprednidene acetate)、氫化皮質酮-17-丁酸酯、氫化皮質酮-17-乙丙酸酯、氫化皮質酮-17-丁丙酸酯、環索奈德(ciclesonide)及潑尼卡酯、GB-0998、益繆格洛(immuglo)、貝格洛瑪(begelomab)、阿法賽特(alefacept)、阿地白介素(aldesleukin)、介維單抗(gevokizumab)、達利珠單抗(daclizumab)、巴利 昔單抗(basiliximab)、伊諾莫單抗(inolimomab)、培米諾近(beperminogene perplasmid)、思魯庫單抗(sirukumab)、托西利單抗(tocilizumab)、科薩單抗(clazakizumab)、美泊利單抗(mepolizumab)、芬戈莫德(fingolimod)、帕比司他(panobinostat)、曲西立濱(triciribine)、尼羅替尼(nilotinib)、伊馬替尼(imatinib)、托法替尼(tofacitinib)、莫羅替尼(momelotinib)、皮非替尼(peficitinib)、抑覃西替尼(itacitinib)、英利昔單抗(infliximab)、PEG-bHb-CO、依那西普(etanercept)、依薩佐米(ixazomib)、硼替佐米(bortezomib)、莫羅莫那(muromonab)、奧昔珠單抗(otelixizumab)、胍立莫司(gusperimus)、貝倫妥單抗維多汀(brentuximab vedotin)、硼絲莫德(Ponesimod)、KRP-203、FG-3019、恩利卡生(emricasan)、促皮質素、依魯替尼(ibrutinib)、西瑞斯(cinryze)、康益斯塔(conestat)、甲氧基聚乙二醇-倍他依泊汀(methoxy polyethylene glycol-epoetin beta)、貝利單抗(belimumab)、布里莫德(blisibimod)、阿塞西普(atacicept)、塞利希布(seliciclib)、內卉麗珠單抗(neihulizumab)、依維莫司(everolimus)、西羅莫司(sirolimus)、地尼白介素迪夫托斯(denileukin diftitox)、LMB-2、那他珠單抗(natalizumab)、卡曲地可(catridecacog)、環孢菌素、他克莫司(tacrolimus)、伏環孢素、伏環孢素、康納單抗(canakinumab)、黴酚酸酯、咪唑立賓(mizoribine)、CE-1145、TK-DLI、阿巴西普(abatacept)、貝拉西普(belatacept)、奧美沙坦美度米(olmesartan medoxomil)、斯帕森坦(sparsentan)、TXA-127、BIIB-023、阿侖單抗(alemtuzumab)、噴司他丁(pentostatin)、意托麗珠單抗(itolizumab)、帕利夫明(palifermin)、來氟米特(leflunomide)、PRO-140、森尼韋若(cenicriviroc)、福他替尼(fostamatinib)、安尼福單抗 (anifrolumab)、絲法力單抗(sifalimumab)、BAX-069、BG-00011、洛嗎莫德(losmapimod)、QPI-1002、ShigamAbs、TZ-101、F-652、瑞帕銳星(reparixin)、蘭達銳星(ladarixin)、PTX-9908、阿伽尼塞(aganirsen)、APH-703、索塔妥林(sotrastaurin)、索塔妥林、米拉珠單抗(milatuzumab)、SM-101、T-Guard、APG-101、DEX-M74、心營養素-1、替普勒斯坦(tiprelestat)、ASKP-1240、BMS-986004、HPH-116、KD-025、OPN-305、TOL-101、去纖維蛋白多核苷酸、泊利度胺(pomalidomide)、抗胸腺細胞免疫球蛋白(Thymoglobulin)、拉喹莫德(laquinimod)、瑞米特塞-L(remestemcel-L)、馬抗胸腺細胞免疫球蛋白、斯丹標塞(Stempeucel)、LIV-γ、10%奧克塔加(Octagam 10%)、t2c-001、99mTc-塞坦米必(99mTc-sestamibi)、克萊瑞格(Clairyg)、普若索拔(Prosorba)、泊利度胺、拉喹莫德、替利珠單抗(teplizumab)、FCRx、索那替德(solnatide)、福然單抗(foralumab)、ATIR-101、BPX-501、ACP-01、ALLO-ASC-DFU、依貝沙坦+丙帕鍺(irbesartan+propagermanium)、ApoCell、大麻二酚、RGI-2001、乳清酸、抗CD3二價抗體-白喉毒素共軛物、NOX-100、LT-1951、OMS721、ALN-CC5、ACH-4471、AMY-101、阿卡瑟凝膠(Acthar gel)及CD4+CD25+調節性T細胞,及其組合。
- 一種如請求項1至19中任一項之化合物或其醫藥學上可接受之鹽或如請求項20至24中任一項之醫藥組合物之用途,其係用於製造用以治療罹患或易患涉及C5a受體之病理性活化之疾病或病症的人類的藥劑。
- 如請求項25之用途,其中該疾病或病症為發炎性疾病或病症、自體免疫疾病或致癌性疾病或病症。
- 如請求項25之用途,其中該疾病或病症為心血管病症或腦血管病症。
- 如請求項25之用途,其中該疾病或病症選自由以下各者組成之群:嗜中性白血球減少症、嗜中性白血球增多症、韋格納氏肉芽腫病(Wegener's granulomatosis)、顯微鏡下多血管炎、C3-腎絲球病變、C3-絲球體腎炎、密度沈積病、膜增生性絲球體腎炎、川崎病(Kawasaki disease)、敗血症、敗血性休克、溶血性尿毒症症候群、非典型性溶血性尿毒症症候群(aHUS)、阿茲海默氏病(Alzheimer's disease)、多發性硬化症、中風、發炎性腸病、慢性阻塞性肺疾病、與燒傷相關的發炎、肺損傷、骨關節炎、異位性皮炎、慢性蕁麻疹、缺血-再灌注損傷、急性呼吸窘迫症候群、全身性發炎反應症候群、多器官功能障礙症候群、葡萄膜炎、組織移植物排斥反應、經移植器官之超急性排斥反應、心肌梗塞、冠狀動脈血栓、血管閉塞、手術後血管再閉塞、動脈粥樣硬化、息肉狀脈絡膜血管病變、創傷性中樞神經系統損傷、缺血性心臟病、類風濕性關節炎、全身性紅斑性狼瘡症、格-巴二氏症候群(Guillain-Barre syndrome)、胰臟炎、狼瘡性腎炎、狼瘡性絲球體腎炎、牛皮癬、克隆氏病(Crohn's disease)、血管炎、ANCA血管炎、大腸急躁症候群、皮肌炎、多發性硬化症、支氣管哮喘、天疱瘡、類天疱瘡、硬皮病、重症肌無力、自體免疫溶血性及血小板減少性病況、古德巴士德氏症候群(Goodpasture's syndrome)、免疫血管炎、移植物抗宿主疾病、陣發性夜間血紅素尿症、休格連氏症候群(Sjoegrens syndrome)、胰島素依賴型糖尿病、狼瘡性腎病變、海曼腎炎(Heyman nephritis)、膜性腎炎、絲球體腎炎、IGA腎病變、膜增生性絲球體腎炎、抗磷脂症候群、年齡相關黃斑變性、乾式年齡相關黃斑變性、濕式年齡相關黃斑變性、運動神經元疾病、接觸性敏感性反應及由血液與人造表面接觸所引起之發炎。
- 如請求項25之用途,其中該疾病或病症選自由以下各者組成之群:嗜中性白血球減少症、嗜中性白血球增多症、韋格納氏肉芽腫病、顯微鏡下多血管炎、C3-腎絲球病變、C3-絲球體腎炎、密度沈積病、膜增生性絲球體腎炎、川崎病、溶血性尿毒症症候群、非典型性溶血性尿毒症症候群(aHUS)、組織移植物排斥反應、經移植器官之超急性排斥反應、類風濕性關節炎、全身性紅斑性狼瘡症、狼瘡性腎炎、狼瘡性絲球體腎炎、血管炎、ANCA血管炎、自體免疫溶血性及血小板減少性病況、免疫血管炎、移植物抗宿主疾病、狼瘡性腎病變、海曼腎炎、膜性腎炎、絲球體腎炎、IGA腎病變、膜增生性及絲球體腎炎。
- 如請求項25之用途,其中該疾病或病症選自由以下各者組成之群:黑色素瘤、肺癌、淋巴瘤、肉瘤、癌瘤、纖維肉瘤、脂肪肉瘤、軟骨肉瘤、骨原性肉瘤、血管肉瘤、淋巴管肉瘤、滑膜瘤、間皮瘤、腦膜瘤、白血病、淋巴瘤、平滑肌肉瘤、橫紋肌肉瘤、鱗狀細胞癌、基底細胞癌、腺癌、乳頭狀癌、囊腺癌、支氣管癌、腎細胞癌、肝細胞癌、移行細胞癌、絨膜癌、精細胞癌、胚胎性瘤、威爾姆斯瘤(wilm's tumor)、多形性腺 瘤、肝細胞乳頭狀瘤、腎源性小管性腺瘤、囊腺瘤、乳頭狀瘤、腺瘤、平滑肌瘤、橫紋肌瘤、血管瘤、淋巴管瘤、骨瘤、軟骨瘤、脂肪瘤及纖維瘤。
- 如請求項25至30中任一項之用途,其中該藥劑與一或多種其他治療劑組合使用。
- 如請求項31之用途,其中該一或多種其他治療劑選自由以下各者組成之群:皮質類固醇、類固醇、免疫抑制劑、免疫球蛋白G促效劑、二肽基肽酶IV抑制劑、淋巴細胞功能抗原-3受體拮抗劑、介白素-2配位體、介白素-1 β配位體抑制劑、IL-2受體α次單位抑制劑、HGF基因刺激劑、IL-6拮抗劑、IL-5拮抗劑、α 1抗胰蛋白酶刺激劑、類大麻鹼受體拮抗劑、組蛋白脫乙醯基酶抑制劑、AKT蛋白激酶抑制劑、CD20抑制劑、Abl酪胺酸激酶抑制劑、JAK酪胺酸激酶抑制劑、TNF α配位體抑制劑、血紅蛋白調節劑、TNF拮抗劑、蛋白酶體抑制劑、CD3調節劑、Hsp 70家族抑制劑、免疫球蛋白促效劑、CD30拮抗劑、微管蛋白拮抗劑、神經鞘胺醇-1-磷酸酯受體-1促效劑、結締組織生長因子配位體抑制劑、卡斯蛋白酶抑制劑、促腎上腺皮質激素配位體、Btk酪胺酸激酶抑制劑、補體C1s子組分抑制劑、紅血球生成素受體促效劑、B-淋巴細胞刺激子配位體抑制劑、週期蛋白依賴型激酶-2抑制劑、P-選擇素醣蛋白配位體-1刺激劑、mTOR抑制劑、延長因子2抑制劑、細胞黏附分子抑制劑、XIII因子促效劑、鈣調神經磷酸酶抑制劑、免疫球蛋白G1促效劑、肌核苷單磷酸去氫酶抑制劑、補體C1s子組分抑制劑、胸苷激酶調節劑、細胞毒性T-淋巴細胞蛋白- 4調節劑、血管緊張素II受體拮抗劑、血管緊張素II受體調節劑、TNF超家族受體12A拮抗劑、CD52拮抗劑、腺苷脫胺酶抑制劑、T細胞分化抗原CD6抑制劑、FGF-7配位體、二氫乳清酸去氫酶抑制劑、CCR5趨化介素拮抗劑、CCR2趨化介素拮抗劑、Syk酪胺酸激酶抑制劑、I型干擾素受體拮抗劑、α干擾素配位體抑制劑、巨噬細胞遷移抑制因子抑制劑、整合素α-V/β-6拮抗劑、半胱胺酸蛋白酶刺激劑、p38 MAP激酶抑制劑、TP53基因抑制劑、志賀樣毒素I抑制劑、海藻糖基轉移酶6刺激劑、介白素22配位體、CXCR1趨化介素拮抗劑、CXCR4趨化介素拮抗劑、IRS1基因抑制劑、蛋白激酶C刺激劑、蛋白激酶C α抑制劑、CD74拮抗劑、免疫球蛋白γ Fc受體IIB拮抗劑、T細胞抗原CD7抑制劑、CD95拮抗劑、N乙醯甘露糖胺激酶刺激劑、心營養素-1配位體、白細胞彈性蛋白酶抑制劑、CD40配位體受體拮抗劑、CD40配位體調節劑、IL-17拮抗劑、TLR-2拮抗劑、甘露聚糖結合凝集素絲胺酸蛋白酶-2(MASP-2)抑制劑、B因子抑制劑、D因子抑制劑及T細胞受體拮抗劑,及其組合。
- 如請求項31之用途,其中該一或多種其他治療劑選自由以下各者組成之群:歐比托珠單抗、利妥昔單抗、奧克珠單抗、環磷醯胺、潑尼松、氫化皮質酮、氫化皮質酮乙酸酯、皮質酮乙酸酯、替可的松特戊酸酯、潑尼龍、甲基潑尼龍、曲安奈德、曲安西龍醇、莫米松、安西奈德、布地奈德、地奈德、氟西奈德、丙酮化氟新龍、哈西奈德、倍他米松、倍他米松磷酸鈉、地塞米松、地塞米松磷酸鈉、氟可龍、氫化皮質酮-17-戊酸酯、鹵米松、阿氯米松二丙酸酯、倍氯米松、倍他米松戊酸酯、倍他米松二丙酸酯、潑尼卡酯、氯倍他松-17-丁酸酯、氯倍他索-17-丙酸酯、氟可龍己 酸酯、氟可龍特戊酸酯、氟潑尼定乙酸酯、氫化皮質酮-17-丁酸酯、氫化皮質酮-17-乙丙酸酯、氫化皮質酮-17-丁丙酸酯、環索奈德及潑尼卡酯、GB-0998、益繆格洛、貝格洛瑪、阿法賽特、阿地白介素、介維單抗、達利珠單抗、巴利昔單抗、伊諾莫單抗、培米諾近、思魯庫單抗、托西利單抗、科薩單抗、美泊利單抗、芬戈莫德、帕比司他、曲西立濱、尼羅替尼、伊馬替尼、托法替尼、莫羅替尼、皮非替尼、抑覃西替尼、英利昔單抗、PEG-bHb-CO、依那西普、依薩佐米、硼替佐米、莫羅莫那、奧昔珠單抗、胍立莫司、貝倫妥單抗維多汀、硼絲莫德、KRP-203、FG-3019、恩利卡生、促皮質素、依魯替尼、西瑞斯、康益斯塔、甲氧基聚乙二醇-倍他依泊汀、貝利單抗、布里莫德、阿塞西普、塞利希布、內卉麗珠單抗、依維莫司、西羅莫司、地尼白介素迪夫托斯、LMB-2、那他珠單抗、卡曲地可、環孢菌素、他克莫司、伏環孢素、伏環孢素、康納單抗、黴酚酸酯、咪唑立賓、CE-1145、TK-DLI、阿巴西普、貝拉西普、奧美沙坦美度米、斯帕森坦、TXA-127、BIIB-023、阿侖單抗、噴司他丁、意托麗珠單抗、帕利夫明、來氟米特、PRO-140、森尼韋若、福他替尼、安尼福單抗、絲法力單抗、BAX-069、BG-00011、洛嗎莫德、QPI-1002、ShigamAbs、TZ-101、F-652、瑞帕銳星、蘭達銳星、PTX-9908、阿伽尼塞、APH-703、索塔妥林、索塔妥林、米拉珠單抗、SM-101、T-Guard、APG-101、DEX-M74、心營養素-1、替普勒斯坦、ASKP-1240、BMS-986004、HPH-116、KD-025、OPN-305、TOL-101、去纖維蛋白多核苷酸、泊利度胺、抗胸腺細胞免疫球蛋白、拉喹莫德、瑞米特塞-L、馬抗胸腺細胞免疫球蛋白、斯丹標塞、LIV-γ、10%奧克塔加、t2c-001、99mTc-塞坦米必、克萊瑞格、普若索拔、泊利度胺、 拉喹莫德、替利珠單抗、FCRx、索那替德、福然單抗、ATIR-101、BPX-501、ACP-01、ALLO-ASC-DFU、依貝沙坦+丙帕鍺、ApoCell、大麻二酚、RGI-2001、乳清酸、抗CD3二價抗體-白喉毒素共軛物、NOX-100、LT-1951、OMS721、ALN-CC5、ACH-4471、AMY-101、阿卡瑟凝膠及CD4+CD25+調節性T細胞,及其組合。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317721P | 2016-04-04 | 2016-04-04 | |
US62/317,721 | 2016-04-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201803850A TW201803850A (zh) | 2018-02-01 |
TWI760331B true TWI760331B (zh) | 2022-04-11 |
Family
ID=59960805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106111387A TWI760331B (zh) | 2016-04-04 | 2017-04-05 | 可溶性C5aR拮抗劑 |
Country Status (18)
Country | Link |
---|---|
US (4) | US20170283446A1 (zh) |
EP (1) | EP3439658B1 (zh) |
JP (1) | JP7121722B2 (zh) |
KR (1) | KR102395093B1 (zh) |
CN (1) | CN109310686B (zh) |
AR (1) | AR108097A1 (zh) |
AU (1) | AU2017246228B2 (zh) |
CA (1) | CA3019137A1 (zh) |
CL (1) | CL2018002803A1 (zh) |
IL (1) | IL261997B (zh) |
MA (1) | MA44629A (zh) |
MX (1) | MX2018011831A (zh) |
NZ (1) | NZ747259A (zh) |
RU (1) | RU2748260C2 (zh) |
SG (1) | SG11201808625QA (zh) |
TW (1) | TWI760331B (zh) |
WO (1) | WO2017176620A2 (zh) |
ZA (1) | ZA201806632B (zh) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2926828T3 (es) | 2014-09-29 | 2022-10-28 | Chemocentryx Inc | Procesos e intermedios en la preparación de antagonistas de C5aR |
TWI791423B (zh) | 2016-01-14 | 2023-02-11 | 美商卡默森屈有限公司 | C3腎絲球病變之治療方法 |
CN109310686B (zh) | 2016-04-04 | 2022-06-21 | 凯莫森特里克斯股份有限公司 | 可溶性C5aR拮抗剂 |
WO2018184739A1 (en) | 2017-04-03 | 2018-10-11 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
MA48803A (fr) | 2017-05-31 | 2020-04-08 | Chemocentryx Inc | Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a |
EP3630774B1 (en) | 2017-05-31 | 2022-11-23 | ChemoCentryx, Inc. | 5-5 fused rings as c5a inhibitors |
AU2018286754A1 (en) | 2017-06-23 | 2019-12-19 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5A activity |
JP2020532551A (ja) | 2017-09-03 | 2020-11-12 | アンジオン バイオメディカ コーポレーション | Rho関連コイルドコイルキナーゼ(ROCK)阻害剤としてのビニルヘテロ環 |
US20190144389A1 (en) | 2017-10-30 | 2019-05-16 | Chemocentryx, Inc. | Deuterated compounds as immunomodulators |
KR20200109297A (ko) * | 2017-10-31 | 2020-09-22 | 케모센트릭스, 인크. | 소변 sCD163의 C5aR 억제제 감소 |
JP2021505659A (ja) * | 2017-12-01 | 2021-02-18 | ソリシメド バイオファーマ インコーポレイテッド | 癌治療のためのtrpv6阻害剤および併用療法 |
KR20200109316A (ko) | 2017-12-22 | 2020-09-22 | 케모센트릭스, 인크. | C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물 |
CA3086111A1 (en) | 2017-12-22 | 2019-06-27 | Chemocentryx, Inc. | Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors |
US20190300526A1 (en) | 2018-04-02 | 2019-10-03 | Chemocentryx, Inc. | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
WO2019200030A1 (en) * | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
US11191756B2 (en) | 2018-06-07 | 2021-12-07 | Chemocentryx, Inc. | Dosing and effect of C5a antagonist with ANCA-associated vasculitis |
MD3886820T2 (ro) | 2018-11-30 | 2023-07-31 | Chemocentryx Inc | Formulări de capsule |
CN113490511A (zh) * | 2019-02-26 | 2021-10-08 | 伊奎利厄姆股份有限公司 | 用于治疗狼疮的抗cd6抗体组合物和方法 |
CN111658647A (zh) * | 2019-03-08 | 2020-09-15 | 首都医科大学宣武医院 | 沙利度胺及其衍生物的用途 |
KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
CA3145303A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
CA3148495A1 (en) * | 2019-09-04 | 2021-03-11 | Stanley C. Jordan | Use of calcineurin inhibitor free ctla4-ig + anti-il6/il6r for long term immunosuppression in solid organ transplant recipients |
EP3868368A1 (en) * | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
IL296036A (en) | 2020-03-27 | 2022-10-01 | Inflarx Gmbh | c5a inhibitors for the treatment of corona virus infection |
WO2022057910A1 (en) * | 2020-09-17 | 2022-03-24 | I-Mab Biopharma Co., Ltd | Combination therapies targeting c5ar and pd-1/pd-l1 pathways |
EP4237411A1 (en) | 2020-10-28 | 2023-09-06 | ChemoCentryx, Inc. | Methods of treating hidradenitis suppurativa |
MX2023007420A (es) * | 2020-12-21 | 2023-06-29 | Chemocentryx Inc | Tratamiento de glomerulopatia c3 usando un inhibidor de c5a. |
IT202100019454A1 (it) * | 2021-07-22 | 2023-01-22 | Genetic S P A | Process for the preparation of budesonide 21-phosphate |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010075257A1 (en) * | 2008-12-22 | 2010-07-01 | Chemocentryx, Inc. | C5ar antagonists |
WO2011163640A1 (en) * | 2010-06-24 | 2011-12-29 | Chemocentryx, Inc. | C5ar antagonists |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
WO1999033846A2 (en) * | 1997-12-31 | 1999-07-08 | The University Of Kansas | Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof |
JP5260818B2 (ja) | 2000-09-29 | 2013-08-14 | ノバルティス・インターナショナル・ファーマシューティカル・リミテッド | 高親和性低分子C5a受容体調節物質 |
ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
EP1487796A4 (en) | 2002-03-28 | 2005-11-16 | Neurogen Corp | SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR |
EP1487798A4 (en) | 2002-03-28 | 2005-07-13 | Neurogen Corp | Substituted tetrahydroisoquinolines as C5A receptor modulators |
WO2003084524A1 (en) | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
AU2003265625A1 (en) | 2002-08-21 | 2004-03-11 | Neurogen Corporation | Amino methyl imidazoles as c5a receptor modulators |
CA2504941C (en) | 2002-11-08 | 2012-06-26 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
US20060154917A1 (en) | 2003-07-03 | 2006-07-13 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
KR20070011457A (ko) * | 2004-04-09 | 2007-01-24 | 추가이 세이야쿠 가부시키가이샤 | 신규 수용성 프로드럭 |
CN101395158A (zh) | 2006-03-07 | 2009-03-25 | 百时美施贵宝公司 | 可作为激酶抑制剂的吡咯并三嗪苯胺前体药物化合物 |
CN101139358B (zh) | 2006-09-07 | 2011-10-12 | 浙江大德药业集团有限公司 | 乙氧基康普立停及其前药的制备和用途 |
JP2010043063A (ja) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
US8106209B2 (en) * | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
TW201242953A (en) * | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
WO2013032964A1 (en) * | 2011-08-26 | 2013-03-07 | Board Of Regents Of The University Of Nebraska | Compositions and methods for preventing and treating biofilms |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
RS56034B1 (sr) * | 2013-06-11 | 2017-09-29 | Bayer Pharma AG | Derivati prolekova supstituisanih triazolopiridina |
CN109310686B (zh) | 2016-04-04 | 2022-06-21 | 凯莫森特里克斯股份有限公司 | 可溶性C5aR拮抗剂 |
-
2017
- 2017-04-03 CN CN201780022458.9A patent/CN109310686B/zh active Active
- 2017-04-03 RU RU2018138550A patent/RU2748260C2/ru active
- 2017-04-03 CA CA3019137A patent/CA3019137A1/en active Pending
- 2017-04-03 MX MX2018011831A patent/MX2018011831A/es unknown
- 2017-04-03 WO PCT/US2017/025704 patent/WO2017176620A2/en active Application Filing
- 2017-04-03 NZ NZ747259A patent/NZ747259A/en unknown
- 2017-04-03 MA MA044629A patent/MA44629A/fr unknown
- 2017-04-03 EP EP17779588.7A patent/EP3439658B1/en active Active
- 2017-04-03 AU AU2017246228A patent/AU2017246228B2/en active Active
- 2017-04-03 US US15/477,386 patent/US20170283446A1/en not_active Abandoned
- 2017-04-03 SG SG11201808625QA patent/SG11201808625QA/en unknown
- 2017-04-03 KR KR1020187031906A patent/KR102395093B1/ko active IP Right Grant
- 2017-04-03 JP JP2019502541A patent/JP7121722B2/ja active Active
- 2017-04-04 AR ARP170100857A patent/AR108097A1/es unknown
- 2017-04-05 TW TW106111387A patent/TWI760331B/zh active
-
2018
- 2018-02-28 US US15/908,508 patent/US10329314B2/en active Active
- 2018-09-27 IL IL261997A patent/IL261997B/en unknown
- 2018-10-02 CL CL2018002803A patent/CL2018002803A1/es unknown
- 2018-10-05 ZA ZA2018/06632A patent/ZA201806632B/en unknown
-
2019
- 2019-03-19 US US16/357,889 patent/US10487098B2/en active Active
- 2019-10-23 US US16/660,994 patent/US11254695B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010075257A1 (en) * | 2008-12-22 | 2010-07-01 | Chemocentryx, Inc. | C5ar antagonists |
WO2011163640A1 (en) * | 2010-06-24 | 2011-12-29 | Chemocentryx, Inc. | C5ar antagonists |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI760331B (zh) | 可溶性C5aR拮抗劑 | |
TWI791423B (zh) | C3腎絲球病變之治療方法 | |
JP7337833B2 (ja) | 縮合二環式C5aRアンタゴニストのプロドラッグ | |
CN111788184B (zh) | 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物 | |
TW201927782A (zh) | 作為C5aR抑制劑之經二芳基取代之6,5-稠合環化合物 | |
CA3108099A1 (en) | Tlr7/8 antagonists and uses thereof | |
JP2022554019A (ja) | 補体成分C5a受容体の遊離塩基結晶形態 | |
JP2023501789A (ja) | 補体成分C5a受容体の非晶質形態 | |
US11427541B2 (en) | Salt forms of a complement component C5A receptor | |
CA3174145A1 (en) | Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins | |
BR112018070214B1 (pt) | ANTAGONISTAS C5Ar SOLÚVEIS, COMPOSIÇÕES FARMACEUTICAS E SEUS USOS |